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Abstract
Glutamate carboxypeptidase II (GCPII) is a transmembrane zinc metalloprotease
expressed in a number of organisms: from yeast to worm to humans. In humans, GCPII
has been observed as a multifunctional protein and expressed in prostate, intestine, kidney,
brain, tumor-associated neovasculature and other tissues as five paralogs. In the human
small intestine, hGCPII is proposed to facilitate the folate absorption by cleaving terminal
glutamate residues in dietary folates. Folates act as a cofactor in one-carbon metabolic
pathways such as nucleotide synthesis, amino acid synthesis, DNA repair, and
consequently involved in cell division and growth. The hGCPII homolog is found in the
nematode Caenorhabditis elegans (cGCPII) as three paralogs and shares a high structural
similarity with hGCPII. In this study, the C. elegans strains: wild-type (N2), and gcp-2
deletion mutant strains: RB 1055 (gcp-2 .1), TM6632 (gcp-2 .2) and TM5414 (gcp-2 .3) were
used to investigate the role of gcp-2 in folate metabolism. This study shows that the gcp2 .1 and gcp-2 .2 paralogs play a significant role in folate metabolism, reproduction, and

embryonic and post-embryonic development in C.elegans. When the gcp-2 mutant worms
were fed with a folate-deficient diet, it showed folate deficient phenotypes, infertility and
growth retardation, as observed in mice and humans. This work establishes, for the first
time, the relationship between GCPII and folate metabolism in C. elegans as proposed for
human folate metabolism. This study demonstrates that C. elegans can be used as a
genetically tractable model organism to invetigate the tissue-specific multifunctional roles
of GCPII in development and reproduction of a multicellular organsim.
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Chapter 1: Introduction
1.1 Proteases

Proteases, also known as proteolytic enzymes, peptidases or proteinases, are
enzymes that catalyze the cleavage of peptide bonds between amino acid residues in a
polypeptide chain or molecules containing peptide bonds (I). These enzymes were
believed to appear at the initial stages of protein evolution in primitive organisms as a
destructive enzyme for protein catabolism and amino acids production. Proteases play an
essential role in metabolism such as regulation of protein degradation, localization, and
activity, modulation of protein-protein interactions, production of bioactive molecules, and
signal generation, transduction and amplification. Thus, involved in replication and
transcription of DNA, cellular proliferation and differentiation, tissue morphogenesis and
remodeling, heat shock and unfolded protein responses, angiogenesis, neurogenesis,
ovulation, fertilization, wound repair, stem cell mobilization, hemostasis, blood
coagulation, inflammation, immunity, autophagy, senescence, necrosis, and apoptosis (2).
Based on the catalytic mechanisms, proteases fall into six classes: aspartic,
glutamic, metalloproteases, cysteine, serine, and threonine proteases. Glutamic proteases
are not present in mammals. The first three classes attack the peptide bond of the substrate
by activating a water molecule to serve as the nucleophile, while the rest attack the peptide
bond of the substrate by utilizing a catalytic amino acid residue (cysteine, serine, and
threonine respectively) located in the active site as the nucleophile (Figure 1). These
protease classes can be further branched based on the amino acid sequence and
characteristics of their three-dimensional folding (2, 3). According to the Mammalian
Degradome Database (4, 4), there are 588, 658, 658 total number of protease genes present
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in human, rat and mouse genomes respectively. Human catalytic classes; aspartic, cysteine,
metallo, serine and threonine proteases has 21 , 164, 192, 184 and 27 different members
respectively (4). The protein Glutamate Carboxypeptidase II (GCPII), the subject of this
thesis, is a metalloprotease.

b

c

d

Figure 1. Catalytic Mechanisms of Proteases.

(a) serine proteases; (b) cysteine proteases; (c) aspartyl proteases; and (d) metalloproteases

(5).
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1.2 Metalloprotease and M28 family

Metalloproteases are the largest subclass of proteases with 192 members in humans
(4). This is a vastly diverse group of proteases distributed across families Ml through M91,
each family represents a set of homologous proteases (6). The active site of
metalloproteases consists one or two divalent metal ions to catalyze the hydrolytic cleavage
of the peptide bonds as shown in Figure lb (7, 8). These metal ions are bound in an
approximate tetrahedral conformation at the active site. The catalytic metal ion coordinates
with three amino acid residues of the substrate polypeptide chain and a water molecule.
These amino acid residues are usually charged (9). Metalloproteases usually employ Zinc
ion (Zn2+) (10). Other transition metals such as Co2+ and Mn2+ have been found at active
sites. GCPII is a Zn-metalloprotease.
Based on the cleavage site of the hydrolysis-targeted protein there are two
subgroups

of

metalloproteases:

metalloendopeptidase

and

metalloexopeptidase.

Metalloendopeptidase cleave a terminal peptide bond, while metalloendopeptidases cleave
an internal peptide bond (11 ). Metalloendopeptidases can be further divided as
aminopeptidases and carboxypeptidases which hydrolyzes the first peptide at the amino
terminal (N-terminus) and carboxyl terminal (C-terminal) end of protein substrates
respectively (12, 13).
Peptidases in M28 family have co-catalytic zinc ions, meaning that two Zn2+ ions
act together in the active site, and such active sites are found in aminopeptidases and
carboxypeptidases. Each Zn2+ is coordinated in tetrahedral conformation with three amino
acid residues and a catalytic water molecule. An aspartate residue binds Zn2+. The Zn2+
ligands (with the bound metal ion indicated by Roman Figures) occur in the sequence in
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the order His (II), Asp (I and II), Glu (I), Asp or Glu (II) and His (I). Two additional
residues, an Asp and a Glu, are believed to be important for catalysis. Four of these residues
appear in the motifs His-Xaa-Asp and Glu-Glu (14-16).

1.3 Glutamate Carboxypeptidase (GCPII)

In 1985, Koller and Coy le (17, 18) discovered a novel enzyme that cleaves the
peptide neurotransmitter N-acetyl-l-aspartyl-l-glutamate (NAAG) and consequently
termed as N-acetylated-alpha-linked acidic dipeptidase (NAALADase ). In 1987 (19), a
novel monoclonal antibody was found upon immunizing isolated LNCaP cells of human
prostate malignant. The antigen of this antibody was believed to be prostate specific.
Hence, termed as prostate specific membrane antigen (PSMA). In 1996 (20), it was
discovered that PSMA has similar NAAG hydrolytic activity, pharmacologic properties
and high sequence identity to NAALADase. Therefore, NAALADase and PSMA refer to
one protein. In the same year Pinto et al (21) found that PSMA possess folate hydrolase
activity or acts as a pteroyl poly-gamma-glutamyl carboxypeptidase (21, 22).
NAALADase, PSMA and folate hydrolase are now known with the unified name
Glutamate Carboxypeptidase II (GCPII; EC 3.4.17.21) approved by the International
Union of Biochemistry and Molecular Biology (23). This is a transmembrane, zincdependent metalloprotease belonging to M28 family (described above in Chapter 1.2) (23,
24). GCPII is identified in many different organisms including Homo sapiens (human),

Caenorhabditis elegans (soil nematode) and Mus musculus (mouse). Human GCPII
(hGCPII) is encoded by folate hydrolase (FOLHl) gene (24). GCPII has been extensively
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studied over the last three decades as a therapeutic target for various neurological and
oncological diseases.

1.3.1 Localization and Physiological Role

hGCPII is expressed in the central and peripheral nervous system, small intestine,
kidney and tumor-associated neovasculature with the highest expression levels present in
astrocytes and testis (24, 25). In astrocytes and Schwann cells, it modulates excitatory
neurotransmission by hydrolyzing the neuropeptide NAAG into N-acetyl-1-aspartate and
glutamate, which is the major excitatory neurotransmitter in the brain (Figure 2). Then
released glutamate binds to metabotropic glutamate receptor-I (mGluR-1) on astrocytes to
initiate Ca2+ waves, which increases neuron excitability (26, 27). Therefore, overexpression of hGCPII in the central nervous system instigates glutamate excitotoxicity (2830). Glutamate is the major excitatory neurotransmitter in the mammalian brain. Therefore,
prolonged exposure to glutamate leads excessive influx of ions into the neuronal cells
resulting calcium overload which is toxic to neurons. This results in activation of enzymes
that degrade proteins, membranes and nucleic acids leading to the damage and death of
neurons. This is known as glutamate excitotoxicity (31 ). This can lead to stroke, traumatic
brain injury and neurodegenerative diseases such as Alzheimer's disease, Parkinson's
disease, Huntington's disease and amyotrophic lateral sclerosis (28-30). Pharmacological
inhibition and genetic knock down of GCPII in tissue culture and animal models was
shown to be neuroprotective. Thus, GCPII is a putative therapeutic target (32, 33).
In the jejunum, GCPII aids absorptions of dietary folates by cleaving folly-poly-yglutamate into folate and glutamate (Figure 27) (32). Then folate is absorbed by enterocytes
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via reduced folate carriers and folate binding proteins. Mutations in GCPII is associated
with folate malabsorption resulting depression, anemia, infertility, Crohn' s disease and
inflammatory bowels disease. Folate deficiency during pregnancy can lead to infants with
severe birth defects of spine and skull, termed neural tube defects (NTDs) and child
developmental delay (34). The role GCPII in folate metabolism is further discussed in the
Chapter 3 under section 4.
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Figure 2. The mechanism of GCPII action in the brain.
(A) Pathway of NAAG hydrolysis and excitatory neurotransmission in astrocytes. (B)
Hydrolysis of NAAG by GCPII. NAAG, N-acetyl-1-aspartyl-l-glutamate; NAA, Nacetylaspartate; Glu, glutamate; mGluRl , metabotropic glutamate receptor-I.
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GCPII is highly expressed in prostate carcinoma cells. Therefore, GCPII is an
established cancer marker as the expression is corelated with the progression of prostate
cancer. Although the role in prostate cancer progression is unknown, several studies have
liked its role to tumor progression (35). It is also expressed in the neovasculature of
including glioblastomas, breast, bladder and lung cancers (35 , 36). Thus, GCPII is a
potential target for anti-tumor therapy. The roles of GCPII in prostate, kidney and many
other tissues remain unknown.

1.3.2 Structure

GCPII is encoded by FOLHl gene which has19 exons spanning 60 Kilobases (Kb)
of genomic DNA. The GCPII cDNA is 2.65 Kb long, which is mapped to chromosome 11
and translates into a 750 amino acid protein (35 , 37). As shown in Figure 3, GCPII is type
II transmembrane protein with a short cytoplasmic N-terminal sequence of 1-18 amino acid
residues (aa), a single transmembrane helix of 19-43 aa and a large extracellular C-terminal
sequence of 44-750 aa. The N-terminal portion modulates GCPII endocytosis by
interacting with membrane scaffold proteins such as clathrin, clathrin adaptor protein-2,
caveolin-land filamin-A (24, 35). Thus, N-terminal sequence is pivotal to recycle and
internalize GCPII. The large C-terminal portion is a single subunit; however, it can be
subdivided into three structurally distinct domains : protease domain consists of 57-116 aa
and 352-590 aa, apical domain consist of 117-351 aa and dimerization or C-terminal
domain consist of 591-750 aa. Substrate recognition, binding and processing demands
combined action of all three domains (24, 35).
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(117 • 351 aa)

Active site (Zn" ions)

Protease I
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Figure 3. The structure of human GCPII homodimer (35).
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The secondary structure of GCPII is organized into a-helices and
4). Protease domain has a central 7 stranded mixed
~ 1 and

~-sheet

~-sheets

(Figure

with 10 flanking a-helices. The

its anti parallel strands links protease and apical domains. Apical domain is inserted

between the central ~ 1 and

~2

strands. C-terminal domain consists 4 a-helices and two of

these a-helix loops that interacts with the protease domain via hydrogen bonding, which
contributes to the tertiary structure (24, 38).
GCPII exhibits C-terminal homodimerization via crystallographic two-fold
symmetry which is fundamental for its catalytic activity. However, these dimers consist
structurally distinct active sites. The C-terminal domain of each monomer is linked by two
salt bridges between arginine662 and asparagine663 . Dimerization is stabilized by a single
Ca2+ that is coordinated by Glu432, Glu436, Thr269 and Tyr272 residues. However, the
Ca2+ do not contribute to the enzymatic activity as it is located away from the active sites
(38).
The active site of GCPII can be divided into two binding pockets: S 1' and S 1. There
is a Zn2+ in each binding pocket (total of 2 Zinc ions) linked by a water molecule. Glu424
in the binuclear Zinc active site acts as the catalytic residue of GCPII. Glu424 accepts a
proton from Zn2+:H20 during substrate cleavage and donate it to the leaving peptide (38).
For example, a proton is transferred to glutamate after attacking the aspartyl carbonyl group
ofNAAG to complete hydrolysis (38 , 39). Sl ' pocket prefers glutamate and glutamate like
moieties binding via H-bonds and ionic interactions. However, the amphipathic nature of
Sl ' allows formation of polar and non-polar interactions like H-bonds, ionic bonds and
hydrophobic and van-der-waals interactions, respectively. Sl pocket is optimized for
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glutamate and aspartate binding Therefore, NAAG and folate naturally become substrates
for GCPII (24).
The molecular weight of the primary GCPII structure is ~ 79 kDa, however, the
molecular weight of folded GCPII complex is 110 kDa (40). This is due to the posttranslational glycosylation modifications. Barinka et al (25) revealed the presence of heavy
N- and 0-glycosylation accounting 10-25% of the total molecular weight of the enzyme.
N-glycosylation is required for proper protein folding and translocation, therefore,
indispensable for its catalytic functions (25). In addition, glycosylation contributes to Cterminal dimerization of the protein. The role of 0-glycosylation is not clear yet (38).

1.3.3 Splice Variants

Several alternative splice variants have been identified in GCPII. These splice
variants were extensively studied in prostate cancer epithelium, thus referred as PSMA
variants. Most alternative splicing occurs at the 5' end. They are PSM-D, PSM-F, PSM-E,
PSM-C, PSMA+68 and PSM' (Figure 5 and Table 1). The wild-type GCPII/PSMA mRNA
contains of 750 aa with 19 exons and 18 introns. PSM' is the first identified splice variant
with 693 aa. This variant lack bases 114-3 79 in the first exon at 3' end and deletions include
the initiation codon. PSM' is abundantly expressed in prostate cancer cells compared to
non-cancerous cells. PSMC and PSMA+68 encodes for a protein with 693 aa. PSM-D and
PSM-F encodes for a protein with 735 by addition of novel 24 aa and deletion of 39 aa.
PSM-E is similar to PSM-F but lacks exon 18 (41).
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Figure 4. The 3D Structure of human GCPII.
Two Zn ligands in the active site are shown as golden spheres. Brown ribbon,

~-sheets;

green ribbon, a-helices; light gray, carbons; cyan, hydrogen; red, oxygen; blue, nitrogen;
yellow, sulfurs. (4)
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Figure 5. Splice variants of GCPII gene (41 ).
ATG is the translation start codon; PSMA is the 'wild-type' GCPII mRNA consisting of
19 exons and 750 aa. Most alternative splicing occurs at the 5' end (i.e. N-terminus of the
protein) and the first three constitutive exons of PSMA: PSMA+68, PSM-E/-F, PSM',
PSM-C, and PSM-D are shown. Yellow, green and red shows alternative exons IA, lB
and 1C. PSM' , PSMC and PSMA +68 encodes for a protein with 693 aa. PSM-D and PSMF encodes for a protein with 735. PSM-E is similar to PSM-F but lacks exon 18.
Crosshatched rectangle indicates the missing region in PSM' compared to PSMA.
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Table 1. Description of splice variants derived from GCPII gene (41 ).

Exon

a Exon

a

Nucleotides

b

FOLHJ genec

1

379

1-379

1+68

447

1-447

1*

113

1-113

lA

97

1797-1893

lB

113

776-908

lC

101

1794-1894

2

106

2499-2604

3

187

8230-8416

number as indicated in the Figure 5

b Number

of nucleotides

cthe size of putative protein products; Sequence of FOLH1 gene stored as "NC_000011"
at NCBI server
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1.3.4 Paralogs, Homologs and Orthologs

Homologs are genes have a common ancestor inherited into two species.
Homologous genes can have similar sequences, but, all similar sequences are not
homologous (42, 43). There are two types of homologous genes: orthologs and paralogs.
Paralogs are products of gene duplication followed by mutations. This is a mechanism of
neofunctionalization in which genes acquire functional divergence. In other words,
paralogs may or may not have the same function after a gene duplication event (44).
Orthologs are products of speciation event followed by gene divergence, in which genes
main function is conserved (42).
Many paralogs and structural homologs of GCPII have been identified in human
proteome and they are predominantly type II transmembrane glycoproteins. Although these
homologs are structurally related, the function remains unknown. However, it is possible
to have non-proteolytic functions. The closest GCPII relative is Prostate specific membrane
antigen-like (PSMAL) with 98% sequence similarity and present only in primates. But it
lacks the entire first exon and a part of the first intron. PSMAL is proteolytically inactive
and this could be a due to extensive N-terminal deletion. PSMAL mRNA has been
identified in human liver, kidney and associated with hearing loss. The second GCPII
homolog is Glutamate Carboxypeptidase III (GCPIII) with 68% sequence similarity and
shows NAAALDase activity. Other homologs are NAALADase Land NAALADase L2
with 37% and 20% sequence similarity, respectively (41).
Identifying GCPII orthologs is important for researchers when selecting suitable
model organisms for research. GCPII is present in many animal species, often in several
paralogs. Murine, rat and porcine GCPII shares >90% sequence similarity with hGCPII.
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However, the tissue specific expression varies. GCPII is absent in mouse, rat, pig, dog or
monkey prostate tissue, where it is largely present in humans. The expression levels in
testis, brain and kidneys of mouse, rat and pig is similar to humans. GCPII is highly
expressed in human and pig intestine, however, absent in mouse and rat intestines (41 ).. C.
elegans have three paralogs of GCPII; gcp-2.1, gcp-2.2 and gcp-2.3. A homologous gene

of GCPII is found in plants known as AMPl which is functionally divergent (45).
Furthermore, this protein is not found in yeasts (41 ).
1.3.5 GCPII in C. elegans

hGCPII and C. elegans GCPII (hereafter identified as cGCPII) shows high
structural similarity when the homology modeling of the extracellular domains of
published human GCPII (hGCPII) was compared the extracellular domains of cGCPII
(unpublished data from Periyannan lab) crystal structure using Modeller program as shown
in the Figure 6. This indicates that both proteins may possess similar functions. Therefore,
used as the model organism for this study. As shown in Figure 7, cGCPII encodes as 3
paralogs compared to 5 paralogs in humans (Chapter 1.3.4): gcp-2.1, gcp-2. 2 and gcp-2. 3.
The gcp-2.1 gene is encoded as 3 isoforms: isoform a, isoform b and isoform c (Table 2)
(46-48).
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hGCPll

cGCPll

Figure 6. Homology modeling of the extracellular domains of published hGCPII (38)
compared to cGCPII crystal structure.
Unpublished cGCPll model generated using Modeller Software and published hGCPII
ectodomain structural data by Periyannan lab).
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Figure 7. Complete mRNA transcript of cGCPII paralogs.
Intrans are indicated by the dense pink boxes. (A) gcp-2.1 paralog encodes as 3 isoforms:
isoform a, isoform band isoform c. (B) gcp-2.2 paralog. (C) gcp-2.3 paralog. (46-48)
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Table 2. Sequences details of cGCPII . (46--48)

Protein a

Transcript b

Protein length c

cGCP-2.1 Isoform a

R57.la.1

d

770

cGCP-2.1 Isoform b

R57.1 b.1

d

576

cGCP-2.1 Isoform c

R57.lc.1

d

751

cGCP-2.2

C35C5.2.1

cGCP-2.3

C35C5.l 1.1 r

a

cGCPII paralog/isoform

b

Coding transcript

c

Number of amino acids

d Shown

e

779
700

in Figure 7 (A)

e

Shown in Figure 7 (B)

f

Shown in Figure 7 (C)

1.3.5 Inhibitors

As discussed above, the involvement of GCPII over-express10n m certain
neurological and oncological diseases elevated the interest for the development of GCPII
inhibitors. These inhibitors must meet two conditions to be effective; presence of
glutamate-like moiety to bind to the C-terminal glutamate recognition site and zinc
chelating group to coordinate the divalent zinc atoms at the active sites. There are three
classes of GCPII inhibitors that has been extensively studied. They are phosphonate-based,
urea-based and thiol-based inhibitors (24).

2-(phosphonomethyl)pentanedioic acid (2-PMP A) (Figure 8) is a phosphonatebased, potent, competitive inhibitor, which was first discovered in 1996 (49). The
glutamate moiety (pentanedioic acid) portion of the inhibitor was designed to interact with
the glutamate recognition site of GCPII, whereas the phosphonate group strongly chelate
the active site zinc ions that contributes to the high potency with a ICso value of 300 pM
(24, 50).

However, 2-PMPA showed poor pharmacokinetic properties; low oral

bioavailability. This directed researchers towards development of small molecule
inhibitors such as 2-(3-mercaptopropyl) pentanedioic acid (2-MPPA) using 2-PMPA as
template (50).
2-MPPA (Figure 8) is a thiol-based, selective, competitive inhibitor with a ICso
value of 90 nM (50). This showed higher oral bioavailability compared to 2-PMPA in
several animal models. However, research discontinued due to its' low potency and
potential immune reactivity in humans (24, 50).
ZJ-43 (Figure 8) is a urea-based inhibitor, which consists NAAG-like analogs.
These analogs have two amino acids joined by their NH2 groups with a urea bond and
employ both the aspartate binding site and glutamate moiety in GCPII. Although, ZJ-43
had shown GCPII inhibition in animal models, like 2-PMPA and 2-MPPA, ZJ-43 also
showed poor pharmacokinetic properties and limited bioavailability (24).
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Figure 8. Structures of GCPII inhibitors. (24)
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1.4 Model Organism: Caenorhabditis elegans

Model organisms are non-human species that helps scientists understand biological
processes, traits or diseases. Therefore, for basic biological and clinical research model
organisms such as C. elegans, Drosophila, Arabidopsis, zebrafish and rodents are essential
tools (51). Typically, model organisms, share several characteristics such as short
generation time,

characterized genome,

inexpensive

cultivation, easy physical

manipulation, availability of genetic/molecul· ·tools and similarity to humans (51, 52).
There are several distinct advantages of C. "''egans makes it an ideal in vivo model
organism to investigate the biological roles of GCPII.
C. elegans, which is commonly known as roundworms, is a multicellular,
eukaryotic, non-hazardous, non-infectious, non-pathogenic, non-parasitic, bacterivore
organism belonging to the phylum Nematoda (53, 54). In the wild, it is often found in soil,
compost and rotting fruits (55). In the laboratory environment, C. elegans are maintained
in petri dishes with agar or liquid culture and usually fed on lawns of the Escherichia coli
strain OP50. However, other bacterial strains can also be used (56). The ability of C.
elegans to grow from egg to egg laying adults in a short generation time

(~3

days) in high

densities, shorter life span and smaller size (~ 1 mm) allows efficient, inexpensive and easy
growth in petri dishes. This model organism has been extensively used for research in
developmental biology, cell biology and neurobiology.

1.4.1 Genetics

C. elegans have two sexes: self-fertilizing hermaphrodites with two copies of the
X chromosome (XX) and males with one copy of the X chromosome (XO) (56, 57).
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Hermaphrodites (Figure 10) are basically females that are capable of producing and storing
sperms for self-fertilization at one stage in their life cycle before they begin the production
of oocytes. (52). Hermaphrodites are also capable of mating with males. However, they are
not able to cross-fertilize with other hermaphrodites. If hermaphrodites self-fertilize, males
appear rarely with a frequency of

~0.1 %

by spontaneous non-disjunction in the

hermaphrodite germ line. Self-fertilization allows homozygous worms to generate
genetically identical progeny (56, 57). However, if a hermaphrodite mate with a male,
males appear at higher frequency of ~50% in which 50% of the offspring does not receive
a copy of the X chromosome from sperm. This is beneficial for breeding with different
worm strains: generate a wild-type sibling of a mutant worm or generate a double mutant
(56).
The C. elegans genome was fully sequenced by the C. elegans Genome Mapping
and Sequencing Consortium and published in 1998 (58). C.elegans genome is 100,291,840
base pair long with six chromosomes and a mitochondrial genome (59, 60). There are
about 20,470 protein-coding genes in the genome (cfhuman genome is estimated to code
for 19,000-22,000 genes) (61, 62). Mutations can be induced by a wide range of mutagens:
chemical mutagenesis or exposure to ionizing radiation (57, 63, 64). This makes C. elegans
a powerful genetic model organism to study genes responsible for a particular biological
trait. The central C. elegans worm stock center, Caenorhabditis Genetics Center at the
University

of

Minnesota

has

over

3000

C.

elegans

mutant

strains

(https://cbs.umn.edu/cgc/home). Deletion mutant strains can also be purchased through the
National Bio-Resource Project (https://shigen.nig.ac.jp/c.elegans/) at the Tokyo Women's
Medical University School of Medicine in Japan. RNA interference (RNAi) is also an
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extensively used technique to regulate gene expression of C. elegans to assess gene
function which is discussed in the Section 1.4.5. Furthermore, recently researchers focused
genome editing tools to generate gene deletions in C. elegans by clustered regularly
interspaced short palindromic repeats (CRISPR)-Cas9 system to induce DNA DoubleStrand Breaks (65, 66). CRISPR Plasmids can be purchased from Addgene plasmid
repository (https://www.addgene.org/crispr/worm/).

1.4.2 RNA Interference (RNAi)

RNAi is a rapid and simple molecular biological method to understand the loss-offunction phenotypes by silencing the gene expression in organisms. Andrew Fire and Craig
Mello received the Nobel Prize for Physiology and Medicine in 2006 for their discovery
of RNAi (67). RNAi stops the gene expression using double stranded, gene specific RNA
(dsRNA) sequences (Figure 9). This dsRNA is then cleaved into short interfering RN As
(siRNAs) by RNase III type endonuclease called "Dicer". These siRNAs are (about 21-25
nucleotides in length) then incorporated into a large nuclease complex known as RNAi
inducing silencing complex (RISC). An enzyme within RISC cleaves mRNA targeted by
siRNAs, thus initiates mRNA degradation as shown in Figure 9 (68-70).
In C. elegans, gene silencing can be induced by introducing siRNA or miRNA
(micro RNA) through microinjection, feeding and soaking. Microinjection involves
mechanical delivery of dsRNA by a needle in which dsRNA is injected directly into the
gonad or the body cavity (69, 71 ). Soaking involves delivery of dsRNA passively through
soaking worms in a solution with dsRNA. Feeding involves transcribing dsRNA into E.
coli and ingesting by C. elegans (71).
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Figure 9. The mechanism of RN Ai. (72)

1.4.3 Anatomy
Adult hermaphrodites have 959 somatic cells with 302 neurons while adult males
have 1031 somatic cells (Figure 10) (52). The anatomy of an adult hermaphrodite is shown
in Figure 10. C. elegans has an unsegmented, cylindrical body shape that is narrowed at
the ends (57). Their body consists two concentric "tubes" : outer tube and inner tube. These
tubes are separated by a fluid filled pseudocoelomic space as shown in Figure 11. The outer
tube (body wall) comprises the cuticle, the hypodermis ("worm skin"), the body-wall
muscles, excretory system and the nervous system (52, 57). Cuticle is a sturdy but
malleable collagenous structure secreted by the underlying epithelium. Cuticle not only
surrounds the outside of worm but also it lines the pharynx and rectum. There are several
pores in the cuticle that open tissues to outside: excretory pore, vulva, anus, lateral lips for
sensilla, and two papillae for anterior deirids. The inner tube consists digestive system with
anterior pharynx which helps in grinding food followed by the intestine that extends along
the body length and ends at the anal pore where waste is passed from the body. In adult
hermaphrodites, the gonad is also found in the pseudocoelomic space (Figure 11£) (52).
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Proximal gonad

Figure 10. Anatomy of an adult hermaphrodite and male.
(A) Differential interference contrast image of an adult hermaphrodite. (B) Schematic
illustration of anatomical structures of the left lateral side of an adult hermaphrodite. See
Figure 11 for cross sections at the levels 2B, 2C, 2D, 2E and 2F. (C) Schematic illustration
of anatomical structures of a male (57)
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A-P

Figure 11. C.elegans cross sections from head to tail.
The level of each cross section is labeled in Figure l 0 (2B-2F). (A) Cross-section at level
2A in Figure I 0. Posterior body. (B) Cross-section at level 2B in Figure I 0. Section through
anterior head. (C) Cross-section at level 2C in Figure 10. Section through the middle of
head. (D) Cross-section at level 2D in Figure 10. Section through posterior head. (E) Crosssection at level 2E in Figure 10. Section through posterior body. DNC, Dorsal nerve cord;
VNC ventral nerve cord. (F) Cross-section at level 2F in Figure I 0. Section through tail,
rectum area. (57)
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1.4.4 The Alimentary System

The alimentary system of an adult hermaphrodite is shown in Figure 12. The
alimentary system can be divided into three sections: foregut (contains the pharynx),
midgut (contains the intestine), and hindgut (contains the rectum and anus) as shown in
Figure 12A. Like in higher eukaryotes, C elegans alimentary system carries out several
functions such as food digestion, nutrient absorption, macromolecule synthesis and storage
and immune response initiation. Furthermore, the intestine also nurtures germ cells through
yolk production (57). When food is consumed via mouth, pharynx pump food into the
intestinal lumen, which runs through the body from the pharynx to the anus (73).
Firstly, when C elegans ingest bacteria (food) through their mouth, a tube-like
muscular pump known as the pharynx is involved in concentrating, grinding and
transporting food to the intestine. Pharynx comprises 9 epithelial, 20 muscle, 9 marginal,
4 gland, 20 neuronal and 6 valve cells. This connects buccal cavity to the intestine (Figure
12A/B) (57, 74).
Secondly, food is transported across the intestine. C elegans intestine contains 20
large epithelial cells. These cells are arranged in bilaterally symmetric pairs (ring-like) to
form a long tube around a lumen (Figure 1 lE and 12). Intestinal lumen is not is firmly
associated with the body wall, but tightly attached to the pharyngeal and rectal valves at
either end. Two intestinal cells are sealed through adherens junctions (Figure 12D). These
cells contain several microvilli extending into the lumen forming a brush border (57, 75).
The main function of intestinal cells is to secrete digestive enzymes into the lumen
and absorb processed nutrients. These cells contain assorted storage granules, therefore,
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act as storage units. In hermaphrodites, the intestinal cells synthesize and secrete yolk
material into the body cavity (57, 75). Then gonads take up the yolk from the body cavity
and transport to the oocytes (76).

Yolk material contain essential nutrients such as

vitellogenin proteins and phospholipids, support embryonic development (77, 78).
Nutrients may also be transported out into non-intestinal cells (57, 75).
Thirdly, after absorption food through the intestine food is transported into hindgut
for excretion. Hindgut contains rectal valve, rectal gland and rectal muscles. Rectal valve
that connects the gut to the rectum and anus in order to excrete intestinal waste to outside.
There are three rectal glands that may secrete digestive enzymes. There are four specialized
rectal muscles in the hindgut that are innervated by motor neurons to generate contractions
in order defecate (57, 79).
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Figure 12. The intestine of an adult hermaphrodite.
(A) Schematic illustration the alimentary system (B) Schematic illustration of intestinal
anatomical structures. Ventral view. (C) Magnified transverse TEM image of the intestinal
lumen. Complex junctions to next to an adherens junction seal two intestinal cells. (D)
Diagram of an intestinal cell cross section showing microvilli . (57)
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1.4.5 Development and Life Cycle

The C. elegans has a rapid life cycle as shown in Figure 13 and starts with the
embryonic stage. The embryonic development can be allocated into two stages:
proliferation and organogenesis. During proliferation, a single cell is divided into

~550

undifferentiated cells. Embryo is released to the environment through vulva opening when
the embryo is 28-30 cells and then embryonic development is completed outside the
hermaphrodite (52, 80). At the end of proliferation, cells are arranged into three germ
layers: ectoderm, mesoderm and endoderm. Ectoderm produces hypodermis and neurons;
mesoderm gives rise to pharynx and muscle whereas endoderm generates germline and
intestine. During organogenesis, cells are terminally differentiated without further cell
division and embryo extends its length to form as an animal with fully differentiated tissues
and organs. At the end of embryonic development, embryos are capable of pharyngeal
pumping and have the general body plan which does not alter during postembryonic
development (80).
After hatching, feeding through pharyngeal pumping stimulates postembryonic
development, in which under favorable conditions, C. elegans go through four larval stages
(named LI , L2, L3 and L4) followed by adulthood as shown in Figure 12. During the
larval stages cells further divide and animals substantially grow (81 ). At the end of each
larval stage worms molt, in which the collagen cuticle is shed and replaced by newly
synthesized cuticle. This allows cuticle to accommodate body growth (80). Additionally,
during larval stages, blast cells divide, sexually dimorphic characteristics such as the
hermaphrodite vulva and male tail arise (52).
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Figure 13. Life cycle of C. elegans at 22

°c.

Life cycle from egg through four larval stages (Ll-L4) to egg laying adult (57, 80).
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However, if C. elegans encounter unfavorable conditions for growth such as high
temperature, limited food or high population density, Ll larva will arrest in development
and progress into an alternative third stage, known as the Dauer stage. Dauer means "to
endure" in German. This stage plays as essential role in long-term survival and C. elegans
can remain in Dauer state for up to 4 months, as they have high lipid stores (stored in
intestinal and skin-like epidermal cells), are non-feeding and highly resistant to stress (52,
82-84). If conditions improve, worms exit the Dauer stage and develop into adulthood as
normal. Post-Dauer stage lifespan is not affected by Dauer stage, therefore, considered as
non-ageing (80, 85).
C. elegans develop from egg to egg laying adult in

brood size of C. elegans

is~

~3

days at 22°C. The average

300. Recently, Pickett et al (86) have shown that the brood

size can vary with the mode of fertilization. When a hermaphrodite was self-fertilized, the
progeny size was

~330

with a reproductive span of ~5 days. When a hermaphrodite was

mated with males, the progeny size increased to ~ 710 with a reproductive span of ~9 days
(86).
Under standard laboratory conditions, the average lifespan is

~2-3

weeks.

Reproduction rate decreases after the initial 3-5 days of adulthood. As aging progresses,
movement declines, neuronal signaling decreases, muscles cell breakdown and mechanical
defense ability deteriorates (87). The lifespan can be influenced by several factors:
temperature, oxygen and diet. For example, previous study (88) showed that mean life span
at 16 °C was

~

23 days while 9 days at 25 °C. In addition, C. elegans cultured in media

with high levels of oxygen showed reduced life span and extended life span at low levels
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of oxygen (89). Furthermore, inducing caloric restriction by growing C. elegans in liquid
media with a low concentration of bacteria increased life span by ~50% (88, 90).
The overall goal of our lab is to understand the catalytic mechanisms and cellular
signaling properties of GCPII. The goal this project is to characterize the functions of
cGCPII in C. elegans. As mentioned in the Section 1.3.5, cGCPII shares high structural
similarity which indicates that it is likely to have similar functions. This encouraged us to
use C. elegans, as a powerful model organism to explore structure-function relationships,
hydrolytic mechanisms, cellular signaling properties, GCPII function and associated
diseases to extrapolate findings to humans.
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Chapter 2: Investigation of the Biological Significance of GCPII in C. elegans
2.1 General Introduction

In this chapter, I intend to characterize the biological functions of cGCPII and
provide a comparative analysis of the phenotypes of C. elegans gcp-2 gene and its paralogs
(gcp-2.1, gcp-2. 2 and gcp-2. 3). This will provide a deeper understating of the role of

cGCPII in reproductive, developmental and physiological characteristics of C. elegans

2.2 Hypothesis and Objectives

The hypothesis that governs this study is that cGCPII plays an essential role in
reproduction, ageing and development of C. elegans. The objectives of this study were to:
1. Establish the role or identify the effect of cGCPII in C. elegans reproduction
2. Establish the role or identify the effect of cGCPII in C. elegans lifespan
3. Establish the role or identify the effect of cGCPII in C. elegans development
4. Establish the role or identify the effect of each gcp-2 paralog in C. elegans
reproduction, lifespan and development
5. The investigate the effect of complete cGCPII knock-down by RNAi

2.3 Materials and Methods
2.3.1 C.elegans and E.coli Strains

Five C. elegans strains used in this study were: N2, RB1055 , TM6632, TM5414
and TM5710 is shown in the Table 3. The N2 and RB1055 were obtained from the
Caenorhabditis Genetics Center; and TM6632, TM5414 and TM5710 were obtained from
the National Bio-Resource Project.
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E. coli

uracil

OP50

auxotroph

a C.

NA

CGC

(94)

elegans allele name

b

C. elegans strain name

c

Sequence name

d

CGC, Caenorhabditis Genetics Center, University of Minnesota; NBRP, National

Bio-Resource Project, Japan
e In

chromosome X; NA, Not Applicable; bp, base pair
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2.3.2 Preparation of Nematode Growth Media (NGM)
Bacterial Food Source

C. elegans are typically feed on E. coli strain OP50 in the laboratory. This bacterial
strain is an uracil auxotroph (i.e. impaired uracil biosynthetic pathway), therefore, the
growth in NGM plates is restricted (56). Stock culture of E. coli strain OP50 was stored in
-80 °C. A frozen (-80 °C) stock of 50 µL OP50 Bacteria was used for the inoculation of
into 100 mL Luria Bertani (LB) broth (Fisher BioReagents). Then the culture was
incubated overnight at 35 °C and 250 rpm using an incubating orbital shaker (New
Brunswick Scientific E24). Bacterial pellet was obtained by centrifuging (Thermo
Scientific Sorvall ST8R) at 3500 rpm for 5 minutes. The bacterial pellet was weighed, and
sterile water was added to normalize the bacterial cell concentration to 200 mg/mL.
LB broth was prepared by adding 25 g LB powder (Casein Peptone 10 g/L, Yeast
extract 5 g/L, Sodium Chloride 10 g/L) into 1 L Millipore water. The media was sterilized
by autoclaving at 120 °C for 45 min.

Preparation of NGM Plates

NGM plates was prepared as described (56) with slight modifications. Briefly, for
1 L NGM medium, 3 g NaCl (Fisher), 2.5 g bacto-peptone (BD™ Difeo™), 17 g technical
agar (BD™ Difeo™) and 975 mL Millipore water were mixed with a magnetic stir bar
until the solution is uniform. This mixture was sterilized by autoclaving at 120 °C for 45
min (Tuttnauer 2540 EP). Media was cooled down to
Scientific Isotemp 205). Once NGM reached

~55

~55

°C using a water bath (Fisher

°C, 25 mL 1 M potassium phosphate

Buffer (pH 6.0), 1 mL lM CaCh, 1 mL 1 M MgS04, 1 mL 5 mg/mL cholesterol (in
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ethanol), 100 mg/mL streptomycin and 1 mL 10 mg/mL nystatin was added and swirled to
mix. 5 mL of the NGM solution was aseptically dispensed into petri dishes (60 x 15 mm)
(Fisherbrand™) using a peristaltic pump (Drummond Scientific) in a sterile hood. Once
medium solidified then the plates were stored at 4 °C in inverted position to preserve
moisture until seeded with OP50. Preparation of stock solutions and liquid growth medium
used in experiments are given in the Appendix 1.

Seeding Plates with E. coli OPSO
100 µL of200 mg/ml E.coli OP50 culture was pipetted onto the center of solidified
NGM plates and swirled plates gently to spread out bacteria culture to cover

~1-inch

diameter circle under sterile conditions.

2.3.3 C. elegans Strain Maintenance
General Maintenance
All strains of C. elegans were maintained on NGM plates seeded with E. coli OP50
in order to ensure that they were available for research when necessary. In order to maintain
a healthy population, worms were transferred onto new plates every two weeks. This can
be done by several methods. The quickest and most convenient method is "chunking" and
mostly used during this study. Chunking involves cutting off an agar section (~0.5 cm2 )
with abundant worms using a sterile spatula and placing onto a new seeded plate. The
spatula was sterilized by passing through flame of the ethanol burner and allowed to cool
down before transferring. The other method is picking single worms with a worm picker
and transferring to new seeded NGM plates. The worm picker was sterilized by passing
through flame of the ethanol burner and allowed to cool down before transferring. Worm
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were maintained at 20 °C in an incubator at all times. Worms can be maintained at room
temperature but that produce slightly different brood size.
The worm picker was made by mounting a ~ 1.5-inch platinum wire into the tip of
a glass Pasture pipet. In order to ensure that wire is attached to the pipette, tip was heated
by the Bunsen burner. The end of the wire was slightly bended making it easy to pick them.

Preparation of frozen C. elegans Stocks
Frozen stocks of C. elegans can be stored at -80

°c. First worms were grown for 4

days in 10 cm NGM plates with 500 µL bacteria at 20 °c. Washed worms off the plates by
adding 10 mL M-9 solution. Worms and M-9 was collected by a Pasteur pipette into a 15
mL conical tube, centrifuged at 2000 rpm for 1 min to pellet worms. Much of the
supernatant was aspirated without disturbing the pellet, 10 mL M-9 solution was added and
resuspended the pellet. Repeated centrifugation - wash cycle twice to ensure there is no
bacteria. To the final aspirated step~ 3 mL M9 supernatant containing worm was as mixed
with equal amount of freezing solution (see Appendix 1). Resuspended the pellet and
transferred 1 mL of the solution (worms) to 1.5 mL sterile microfuge tubes. The tubes with
worms were froze with liquid nitrogen prior to storage at -80 °c.
It is essential to ensure that plates are ready for successful preparation of stocks.

Well-fed worms, adults, eggs and Dauers do not survive well. Worms are ready to freeze
if: (i) there is little or no food (just starved), (ii) plenty of worms at L 1-L2 stages, (iii) some
eggs on the plate and no signs of contamination. If worms starved too long and enter to
Dauer stage, then these worms will not survive the freeze process. Therefore, the plate
needs to have some eggs, which indicate that the plate has not been without food for a long
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time. The worms at early larval (Ll-L2) stages will only survive after freezing, hence, it is
essential to have plenty of L 1-L2s. If the plates are contaminated with other bacteria, then
the worms will continue to eat and grow, thus there will be no stalling at the Ll stage.

2.3.4 Preparation of Age Synchronized Population of C. elegans
This is also known as the worm bleaching protocol. This method was used to obtain
eggs from gravid (egg carrying) adults. In addition, this protocol was used in events of
contamination, as the eggs are free from E.coli. Worms were grown for 3 days and 5 plates
per strain per treatment were used for each experiment. Plates are ready to bleach if: (i)
there are plenty of eggs and egg laying adults, (ii) there is sufficient food and not starved.
Age-synchronized worms were obtained as previously described with slight
modification (95). Synchronized eggs in M9 buffer in a 50 mL conical tube was incubated
overnight at the room temperature with gentle rocking (rocker type). Then 200 µL of L 1
larvae in M-9 solution was transferred to seeded NGM plates and placed at 20 °C. If
controlled number of worms required, then multiple 10 µL solution was used to count the
worms under microscope and the stock solution is either diluted or concentrated (by
pelleting and adding fresh M9) to obtained desired number of worms per milliliter volume.

2.3.5 Brood Size Assay
Brood size was determined by counting the total number progeny from a single
hermaphrodite, as described before (96) using 10 worms per strain. Two replicates were
performed for each experiment. Before counting worms, petri dishes containing progenies
were stored at the 4 °C for at least 30 minutes to inhibit movement to accurately count the
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worms as the worms constantly move across the petri dish if counted at room temperature.
Additionally, drawing a grid on the bottom of petri dish allows counting the number of
worms in each small square, making it easier to keep track of which worms were already
counted. Statistical Analysis was conducted using two-sample t-test assuming equal
variances. p value< 0.001 considered significant. Error bars represent± standard error of
mean (SEM).

2.3.6 Longevity Assay in Solid Media
5-fluoro-2'-deoxyuridine-5'-phosphate (FuDR) containing NGM plates were
prepared by adding 33 µL of 150 mM FuDR stock to 100 mL NGM media that has been
autoclaved, cooled down to 55 °C, mixed well and poured. After overnight hatching of a
synchronized worm population, L 1 worms were transferred onto seeded NGM plates.
These plates were incubated at 20 °C and allowed worms to grow for 24 hrs. Then 10
worms were transferred onto each seeded FuDR containing NGM plates and return to 20
°C. The worms were transferred to a new plate every 5 days to prevent the bacteria from
being depleted. The number of worms alive were recorded every 2 days. Dead worms were
confirmed by gently tapping the worm's head with platinum worm transfer pick. The
worms that failed to respond by moving its head considered as dead and removed from the
plate. Two replicates were performed for each experiment.

2.3. 7 Longevity Assay in Liquid Media
The longevity assay in liquid media was determined the number of worms alive
every 2 days, as described before (97).
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2.3.8 Body Length Measurement
After overnight hatching of a synchronized worm population, LI worms were
transferred onto seeded NGM plates. After 48 hours of incubation at 20 °C, L4 worms were
mounted on 2% agarose pads and paralyzed with a drop of I mM levamisole and examined
with a dissecting microscope (Olympus Model LMS-225R Microscope.). The body length
measurement procedure is shown in Figure 14. Measurements were made from 10 worms
per strain. Two replicates were performed for each experiment. Statistical Analysis was
conducted using two-sample t-test assuming equal variances. p value < 0.001 considered
significant. Error bars represent± SEM.

A

c

B

1: glass slide

view from top:

_ J___O__ J_ _
view from side:

Figure 14. Body length measurement steps (98).
A drop of 1 mM levamisole used as the anesthetizing agent.
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2: laboratory tape (2 layers)
3: 2% agarose solution
4: Pasteur pipet
5: Pipet bulb
6: worm samples
7: coverslip with anesthetizing
agent on top
8: dissection scope

2.3.9 Investigation of the Effect of RNAi
RNAi Feeding Vector

The feeding method of RNAi based gene silencing experiment was followed to
study the expression of gcp-2 genes in C. elegans. C. elegans RNAi feeding vectors were
purchased from Addgene (https://www.addgene.org/1654/). These vectors contained gcp2 genes cloned into the Timmons and Fire feeding plasmid vector (L4440) (Figure 15). The

plasmid L4440 backbone vector was converted by inserting gcp-2 gene-specific DNA
fragments between inverted T7 promoter sites (Figure 16). The backbone of L4440 plasmid
is 2790 bp and ampicillin resistant (99, 100). Four RNAi harboring bacterial strains were
obtained as gift from the University of Texas Health Science Center at Houston: gcp-2.1 strain 1A03; gcp-2.2 - strain 5D09; gcp-2.3 - strain 8D23 ; Vector Control (contains only
the backbone L4440).

RNAi Feeding Strain

L4440 constructs for gcp-2.1, gcp-2.2 and gcp-2.3 were transformed into an
RNaseIII-deficient E. coli strain HTll 5 (DE3). This strain is also referred to as RNAi
feeding strain. HTl 15 was engineered to express T7 RNA polymerase under an isopropyl~-D-thiogalactopyranoside-

(IPTG-) inducible lac promoter (99). In other words, when

IPTG is added to HT115 cells, T7 RNA polymerase is expressed resulting in the
transcription of the inserted gcp-2 genes.
The genotype of E. coli strain HTl 15 is as follows : F-, mcrA, mcrB, IN(rrnDrrnE)l , lambda-, rnc14::Tn10(DE3 lysogen: lavUV5 promoter -T7 polymerase) (IPTGinducible T7 polymerase) (RNase III minus) (99).
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Figure 15. Full Sequence Map ofL4440 RNAi Feeding Vector (100).
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Sma I
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TAGATCTAGAACTAGTGGATCCACCGGTTCCATGGCTAGCCACGTGACGCGTGGATCCCCCGGGCTGCA
Hind Ill

Hine II

Sall
Xho I _____ ~_pa I

K_pn I

GGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATT

Figure 16. The Map of L4440 RNAi Feeding Vector (100).
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Verification of RNAi Feeding Stains
Plasmid Isolation: Plasmids were isolated from all four RNAi plasmid harboring
bacteria using IBI Scientific Plasmid Extraction Kit. Followed manufactures guidelines
(101). Briefly, Harvesting Step: transferred 1.5 ml of cultured RNAi harboring bacterial
cells to a microcentrifuge tube and centrifuge (Thermo Sorvall Legend Micro 17) at 14000
rpm for 1 minute then discarded the supernatant. Re-Suspension Step: Added 200 µl of
PD 1 Buffer to the tube and re-suspended the cell pellet by vortex (Thermolyne ). Lysis

Step: Added 200 µl of PD2 Buffer and mix by inverting the tube ~ 10 times. Then left it at
room temperature 2 minutes. Neutralization Step: Added 300 µl of PD3 Buffer and mixed
by inverting the tubes for

~ 10

times. Centrifuged at 14000 rpm for 3 minutes. DNA

Binding Step: Placed a PD Column in a 2 ml collection tube and the supernatant from the
neutralization step was added. Centrifuged at 14000 rpm for 30 seconds and discarded the
flow-through. Placed the PD Column back in the 2 ml collection tube. Sequencing Step:
Added 400 µL ofWl buffer into the PD Column. Centrifuged at 14000 rpm for 30 seconds
then discarded the flow-through and place the PD Column back in the 2 ml collection tube.

Wash Step: Added 600 µl of Wash Buffer (with ethanol) into the PD Column then
centrifuged at 14000 rpm for 30 seconds and discarded the flow through. Placed the PD
Column back in the 2 ml collection tube. Centrifuged at 14000 rpm for 3 minutes to dry
the column matrix. Placed the PD Column in a new 1.5 ml microcentrifuge tube. DNA

Elution Step: Added 50 µl of Elution Buffer into the center of the PD Column matrix. Left
it for 2 minutes to allow the Elution Buffer to be completely absorbed. Centrifuged at 14000
rpm for 2 minutes to elute the purified DNA. Repeated the elution step.
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Gel Electrophoresis: In order to confirm the plasmid isolation Gel Electrophoresis

was used. Prepared 0.8% agarose gel by adding 0.4 g of agarose (Fisher) to 50 mL lX Trisacetate-EDTA (TAE) buffer. Microwaved for

~1

min until agarose melts and allowed to

cool down 5 ruins. Then added 4 µL ethidium bromide, poured to gel plate and allowed to
solidify for 20 ruins. Wells were loaded with extracted plasmids for each strain: gcp-2.1strain 1A03; gcp-2.2- strain 5D09; gcp-2.3-strain 8D23; and vector control. Connected to
the electrophoresis unit set to ~ 100-110 V until the dye line is approximately 80% of the
way down the gel. This took around 1.5 hours.

Restriction Digestion: Added 1 µL of enzymes: Sacl HF (Bio-Rad) or Hind II

lambda (NEB) was added to 5 µL of lOX NEB Buffer, 5 µL of Extracted Plasmid and 39
µL of nuclease free water. Incubated in water bath set to 37 °C for 2 hours. Prepared the
agarose gel as mentioned in above. Loaded the wells withl 0 µL digested plasmids and 10
µL of EZ Load 100 bp Molecular Ruler (Bio-Rad). For storage, enzymes in digested
plasmid samples were inactivated by 60 °C heat for 20 ruins. Stored at -20 °C. Sacl HF
recognition site is GAGCTC and Hind II recognition site is GTCGAC as shown in Figure
16(102).

Gene - Specific RNAi Primers: RNAi primers specific for gcp-2.1, gcp-2.2 and
gcp-2.3 were obtained from the University of Texas Health Science Center at Houston and

given in the Table 4.
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Table 4. The Gene-Pairs primer sequences (99, 103)
Primer sequences

Product

cDNA
Length

Strain
Left

Right

(bases)

ctcgctcgagtgaaatcatactt

aaaacccatcaaataacatcacg

1630

gtggccggaacagaaaataa

actgtttggatcaacagccc

1165

-

ttgaattttctgccgagctt

ttcctgtc ggtcttgtttcc

1173

-

gcp-2.1

2256

(R57.1)
gcp-2.2

(C35C5.2)
gcp-2.2

(C35C5.l)

RNAi Plasmid Sequencing

RNAi plasmids sequencing was used to determine the proper insertion of the gcp2 gene into the L4440 vector and to verify gcp-2.1, gcp-2.2 and gcp-2.3 gene sequence

using the RNAi primers obtained from the University of Texas Health Science Center at
Houston as mentioned before. DNA sequencing was performed at the Core Sequencing
Facility at the University of Illinois at Urbana-Champaign.
Data analysis was done using the sequence nucleotide alignment tool "BLAST
engine" provided by NCBI, which produces the alignment of two given sequences. (visit:
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_ SPEC=blas
t2seq&LINK_ LOC=align2seq).
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RNAi Feeding Protocol
NGM Feeding Plates: NGM agar plates were prepared as mentioned earlier with
slight modifications. When the autoclaved media was cool down to -55 °C, 1 mM IPTG
(final concentration) and 25 µg/ml Carbenicillin (final concentration) was added but
neither nystatin nor streptomycin was added, to reduce the possibility of these compounds
interfering with the efficacy of RN Ai. Poured plates 5 days before the experiment and dried
at room temperature. It is important that the plates are dried well as if the plates are too
wet, the bacteria may not dry well after seeding and RNAi phenotypes can be weaker (99).

Bacterial Feeding Culture: Frozen -80 °C stock feeding strains that contained
the desired construct were Streaked onto LB agar plates containing 50 µg/mL tetracycline.
Streaked plates were incubated at 37 °C overnight to grow feeding bacterial strains.
Tetracycline will select for feeding competent bacteria (104). A bacterial colony was
picked from the streaked plates with a sterile inoculating loop using sterile technique and
placed in 2 mL of LB broth with 50 µg/mL ampicillin. Incubated overnight at 37 °C and
250 rpm using the orbital shaker. Ampicillin will select for the cloned gene of interest
(104). Did not add tetracycline as inclusion of it during feeding can reduce the efficiency
of RNAi (71, 99). Repeated the previous step in order to get rid of any tetracycline by
inoculating 20 µL of bacterial culture to 2 mL of LB broth with 50 µg/mL ampicillin and
incubated for 3 hat 37 °C and 250 rpm until the optical density is between 0.35 and 0.40.
Seeded 100 µL of culture onto NGM agar plates with Carbenicillin and IPTG (above) and
induced overnight. IPTG should only be added to the NGM plates as addition of IPTG to
overnight culture can reduce efficacy for RNAi (99).
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Transferring C.elegans to RNAi Plates: On the following day, transferred an L4

hermaphrodite onto the first RNAi plate. In order to minimize the amount of E. coli OP50
being transferred, worms were washed with M9 buffer prior to transferring onto RNAi
plates. Plates (with worms) were incubated at 20 °C for 72 hours for RNAi to take effect.
Then transferred adults onto another plate. After 24 hours, removed the adults. Transferred
worms every 24 hours and after three transfers, C elegans progeny were used for brood
size and longevity assay.

2.4 Results
2.4.1 Establish the role of GCPII in C. elegans reproduction

In order to determine the effect of cGCPII in C elegans reproduction, the brood
size assay was conducted in wild-type and gcp-2 mutants as shown in Figure 17.
Quantification of reproduction was measured by the brood size. The data of this experiment
was representative of two biological replicates of five animals each. Data showed that the
progeny size of gcp-2 mutants were decreased compared the wild-type (P < 0.001). The
average brood size of wild-type was 283.l whereas gcp-2.1 mutant, 242.5 (p= l.3471E06); gcp-2.2 mutant, 238.6 (p= 3.24641E-06); gcp-2.3 mutant, 249.8 (p=0.000106744).
Therefore, gcp-2.1 mutants showed 14.3% and gcp-2.2 mutants showed 15.7 % decline in
brood size when compared with the wild-type hermaphrodites. However, gcp-2. 3 mutants
showed relatively lower reduction in progeny size compared to other two mutants, which
is a 11.7% drop compared to the wild-type C elegans. Hence, data indicate that the
reproduction in C elegans is partially affected by absence of gcp-2 paralogs, but not
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completely. Furthermore, it appears that gcp-2 paralogs affect reproduction in C. elegans
at different levels.
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Figure 17. The brood size of wild-type (N2) and gcp-2 mutants.

Mean brood size of wild-type (N2), 283 .1; gcp-2.1 mutant, 242.5 (p= 1.34 71 E-06) ; gcp-

2.2 mutant, 238.6 (p= 3.24641E-06); gcp-2.3 mutant, 249.8 (p=0.000106744). Statistical
significance was determined using two sample T-test (*p > 0.001 , **p < 0.001). **p <
0.001 considered significant. The error bars represent± standard deviation. Data shown are
of two biological replicates of five animals each.
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2.4.2 Establish the role of GCPII in C. elegans aging

In order to determine the effect of GCPII in C. elegans aging, the longevity assay
was conducted in wild-type and gcp-2 mutants. Quantification of the aging was measured
by the longevity and shown in Figure 18. The data of this experiment was representative
of two biological replicates of five animals each. Data showed that the lifespans of gcp-2.1
and gcp-2. 2 mutants are similar to that of the wild-type. However, the survival curve of
gcp-2.3 mutants was slightly shifted towards the left indicating faster death rate. The

observed maximum lifespan for all strains were 25-28 days. The number of worms alive
decreased significantly from 90% to 0% after 14th day in wild-type and gcp-2.1 mutants.
However, in gcp-2.2 and gcp-2. 3 mutants, the number of worms alive significantly reduced
after 10th and 6th day respectively. On the 24th day all worms were dead in wild-type and
gcp-2.1 mutants whereas small percentage of gcp-2.2 and gcp-2. 3 mutants were alive until

the 28th and the 26th day. Hence, data indicates that the longevity is slightly increased by
the absence of gcp-2.1 or gcp-2. 2 and absence of gcp-2. 3 does not show such increase in
longevity. Collectively, these results indicate that gcp-2 mutants differently affect the
longevity of C. elegans. However, the change in the longevities do not appear very
significant.
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Figure 18. The longevity of wild-type and gcp-2 mutants.
Data shown are representative of two biological replicates of five animals each. (A) The
longevity of gcp-2.1 compared to wild-type C. elegans. (B) The longevity of gcp-2.2
compared to wild-type C.elegans. (C) The longevity of gcp-2.3 compared to wild-type C.

elegans. (D) Comparative longevity plot of wild-type and gcp-2 mutants.
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2.4.3 Establish the role of GCPII in C. elegans development

In order to determine the effect of GCPII in C. elegans growth, the body length
assay was conducted in wild-type and gcp-2 mutants. Quantification of the development
was measured by the body length and shown in Figure 19. Previous studies have reported
C. elegans body length as a physiological measurement of development (105, 106). The

images of body length are shown in Figure 20. The data of this experiment was
representative of three biological replicates of five animals each. Data showed that the body
length of gcp-2.1 and gcp-2.2 mutants were higher compared to the wild-type (P < 0.001)
whereas the body length of gcp-2. 3 mutant was lower compared to the wild-type (P <
0.001). The average body length of wild-type was 31.1 whereas gcp-2.1 mutant, 37.4
(p=2.96702E-07); gcp-2.2 mutant, 43.l

(p=9.33288E-13); gcp-2.3 mutant, 28.2

(p=4.82118E-06). Therefore, gcp-2.1 mutants showed 16.8% andgcp-2.2 mutants showed
27.8% increase in body length when compared with the wild-type worms. However, gcp-

2. 3 mutants showed relatively lower body length which is a 10.2% drop compared to the
wild-type C. elegans. Hence, data indicates that the development was affected by absence
of gcp-2 paralogs.
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. Figure 19. The body length of wild-type and gcp-2 mutants.

Mean body length of wild-type, 31.1 µm; gcp-2.1 mutant, 37.4 (p=2.96702E-07); gcp-2.2
mutant, 43.1 (p=9.33288E-13); gcp-2.3 mutant, 28.2 (p=4.82118E-06). Data shown are
representative of three biological replicates of five animals each. Statistical significance
was determined using two sample T-test (*p > 0.001 , **p < 0.001). **p < 0.001 considered
significant. The error bars represent ± standard deviation.
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gcp-2.2

gcp-2.3
Figure 20. The images of the body length of wild-type and gcp-2 mutants.
Images taken on day 2 at 20 °C using an Olympus Model LMS-225R Microscope.
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2.4.4 Establish the role temperature on C. elegans aging and reproduction

In order to determine the effect of temperature and GCPII in C. elegans aging and
reproduction, the longevity and brood size assays were conducted at 26 °C and 20 °C in
wild-type and gcp-2.1 mutant worms as shown in Figure 21 and Figure 22. Quantification
of the aging was measured by the longevity and reproduction was measured by progeny
size. The data of this experiments were representative of 2 biological replicates of five
animals each.
The lifespan of wild-type and gcp-2.1 mutants at 20 °C were similar. The survival
curves of both strains were shifted towards the left at 26 °C in a parallel pattern. Therefore,
wild-type and gcp-2.1 mutant worms showed reduced lifespan as the temperature increases.
The data also indicates that the mutation in gcp-2.1 paralog does not play a role in the
ability of worms to respond increased temperature as both wild-type and gcp-2.1 mutant
worms were similarly affected. The average brood size of wild-type at 20 °C was 247.5
whereas at 26 °C it was reduced to 197.5 (p= 9.91E-06). This is a 20.2% decrease in
progeny size. The average brood size of gcp-2.1 mutant at 20 °C was 221.6 whereas at 26
°C it was reduced to 172. 7 (p= 0.00357). This is a 22% decrease in progeny size. Therefore,
both wild-type and gcp-2.1 mutant hermaphrodites showed decrease in progeny production
as the temperature increases in a parallel pattern. This indicates that gcp-2 paralog does not
play a role in temperature dependent reduction in brood size and lifespan. Furthermore,
data indicates that the lifespan and reproduction was inversely correlated with the
increasing temperature.
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Figure 21. The effect of temperature on longevity of the wild-type and gcp-2.1
mutant C.elegans.
(A) The longevity of wild-type worms at 20 °C and 26 °C (RT). (B) The longevity of gcp2.1 mutant worms at 20 °C and 26 °C (RT).
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Figure 22. The effect of temperature on brood size of the wild-type and gcp-2.1
mutant C.elegans.
The brood size of wild-type and gcp-2.1 mutant worms at 20 °C and 26 °C (RT). Statistical
significance was determined using two sample T-test (*p > 0.005, **p < 0.005). **p <
0.005 considered significant. The error bars represent± SEM. The mean brood size of wildtype at 20 °C, 247.5; at 26 °C, 197.5 (p= 9.91 E-06). The mean brood size of gcp-2.1 mutant
at 20 °C, 221.6; at 26 °C, 172.7 (p= 0.00357). Data shown are representative of two
biological replicates of five animals each.
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2.4.5 Investigation of the Effect of RNAi
Verification of RNAi Feeding Stains

This is a quality control test conducted to verify RNAi feeding strains. First, the
transformation of the feeding vector to into the E. coli HT115 feeding bacteria was
confirmed by gel electrophoresis by detecting the presence of plasmids as shown in the
Figure 23. The proper insertion of the gcp-2.1, gcp-2.2 and gcp-2.3 sequences into the
L4440 vector was determined by RNAi plasmids sequencing.

Gel Electrophoresis

Gel electrophoresis was used to detect the presence of plasmids in feeding bacteria.

RNAi Sequence Alignment

The proper insertion of the gcp-2.1, gcp-2.2 and gcp-2.3 sequences into the L4440
vector was detected by RNAi sequencing and alignment. RNAi plasmid sequencing results
obtained from the Core Sequencing Facility at the University of Illinois at UrbanaChampaign was compared to the known reference sequences if each gcp-2 paralog. gcp2.1 showed 95% (97111027) sequence identity whereas gcp-2.2 and gcp-2.3 showed 99%

(858/867) and 98% (824/837) sequence identity respectively. The alignment results
obtained from the NCBI sequence nucleotide alignment tool "BLAST engine" is shown in
the appendix 3. This indicates that accurate gcp-2.1, gcp-2.2 and gcp-2.3 sequences are
inserted into the L4440 vector.
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Figure 23. The gel electrophoresis images of RNAi plasmids.
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The Effect of RNAi Induced GCP-2 Inhibition on Reproduction

In order to determine the effect of GCPII in C. elegans reproduction using RNAi
mediated GCP-2 knock down technique, the brood size assay was conducted in wild-type
worms shown in Figure 24. Quantification of the reproduction was measured by the brood
size. Wild-type C. elegans were fed with RNAi feeding strains for GCP-2.1, GCP-2.2,
GCP-2.1 and vector control. Additionally, worms were fed with a mixture of feeding
strains (GCP-2.1 , GCP-2.2, GCP-2.1 and vector control) to induce complete knock down
of gcp-2. The data of this experiment was representative of one biological replicate with 5
worms.
The average brood size of wild-type worms fed with vector control was 130.2
whereas GCP-2.1 , 117.8 (p= 0.01932146); GCP-2.2, 129.6 (p= 0.465578589); GCP-2.3,
118.2 (p= 0.029034692) and mixture of all plasmids, 116 (p= 0.073427447). Therefore,
data did not show a significant (p < 0.001) difference between wild-type worms fed with
vector control and GCP-2 plasmids.
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Figure 24. The effect of RNAi induced GCP-2 inhibition on brood size of wild-type
C.elegans.
Mean brood size of wild-type worms fed with vector control, 130.2; GCP-2.1 , 117 .8 (p=
0.01932146); GCP-2.2, 129.6 (p= 0.465578589); GCP-2.3 , 118.2 (p= 0.029034692) and
mixture of all strains, 116 (p= 0.073427447). Statistical significance was determined
using two sample T-test (*p > 0.001 , **p < 0.001). **p < 0.001 considered significant.
The error bars represent± standard deviation. Data shown are representative of 1
biological replicate with 5 worms.
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2.5 Discussion

In this study I describe the role of cGCPII and its paralogs in reproduction, aging
and development of C. elegans. I have shown that gcp-2 paralogs affect these physiological
parameters at different levels. Paralogs as discussed in the Section 1.3.4, is a product of
gene duplication followed by mutations. This is a mechanism of neofunctionalization in
which genes acquire functional divergence. In other words, paralogs can take on a different
function after a gene duplication event (44). Furthermore, sometimes, over a long
evolutionary period, the function and the expression patterns of a paralogous gene pair may
diverge significantly. This will give rise to totally new functions and specializations in the
organism ( 107). Therefore, it is possible that the gcp-2 paralogs may or may not have the
same role in reproduction, aging, development and other physiological functions in any
organism. The reproduction and growth are affected by cGCPII. The absence of gcp-2
paralogs reduce reproduction and growth at different levels in C. elegans. This indicates
that cGCPII play a role in C. elegans reproduction and growth. However, the effect of
cGCPII in longevity does not appear statistically significant.
As discussed in the Chapter 1, hGCPII plays a role in neuronal signaling and folate
absorption. Therefore, the observed deterioration in C. elegans reproduction and growth
can be due to disruptions to cGCPII dependent neuronal signaling or folate metabolism
caused by mutations in gcp-2 paralogs. hGCPII contributes to neural signaling by
hydrolyzing NAAG and producing free

glutamates to induce fast excitatory

neurotransmission through the free glutamate acting on mGlu receptors (Chapter 1). C.
elegans also expresses glutamatergic signaling and 10 genes encoding putative ionotropic

glutamate receptor subunits have been identified ( 108-110). Previous studies using mice
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models had shown that dyshomeostasis of glutamatergic signaling can disrupt insulin
signaling in the brain (111). In C. elegans, mutation in daf-2, a gene encoding an insulin
receptor-like protein, was shown to reduce the progeny size by 20% at 20 °C (112). This
suggests a relationship between glutamate and reproduction through the insulin signaling
pathway. Therefore, the observed reduction in C. elegans reproduction and growth can be
caused by mutated gcp-2 reducing the overall glutamate levels which leads to
reduced/altered insulin signaling. However, it should be noted that NAAG has been
reported as a mammalian neuropeptide and yet there are no reports ofNAAG in C. elegans.
Therefore, if indeed there is link between glutamate-mediated signaling and progeny
production, then the source of glutamate must be established. Additionally, the observed
effect cGCPII in reproduction and growth can also be related to GCPII function in folate
metabolism. This is further discussed in the Chapter 3.
The reduced but statistically significant effect of all three gcp-2 paralogs on the
reproduction and physiological functions may be due to functional complementation by
one gcp-2 paralog for the loss of another gcp-2 paralog in C. elegans as reported (113,
114). When the brood size data is taken into account both gcp-2.1 and gcp-2. 2 paralogs
showed similar but lower brood size than the wild-type and gcp-2.3 paralog. This may
indicate that gcp-2.1 and gcp-2.2 are important paralogs than gcp-2.3 and compensating
each other's role on progeny production. This functional compensation hypothesis is
further strengthened by the fact that none of the paralog shows a striking reduction or
complete abolition of progeny production. Availability of a double mutant of gcp-2.1 and
gcp-2.2 will be an ideal model to test this hypothesis but such double mutants are not

currently available from the worm sources.
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The RNAi experiment did not show a significant difference in reproduction
between the wild-type and gcp-2 mutants. However, whengcp-2 paralogs were genetically
mutated, then there was a significant reduction in brood size of gcp-2 mutants compared to
wild-type. These disparities in results shows that the RNAi experiment was not successful.
Although, the quality control experiments showed that proper gcp-2.1, gcp-2.2 and gcp2. 3 sequences are inserted into the L4440 vector and this vector is transformed into the E.
coli HTl 15 feeding bacteria, it is still possible that the dsRNA production was induced.

This can be confirmed by following methods in a future study ( 115, 116),
•

Real-time quantitative PCR (RT-qPCR) to quantify the knockdown of the mRNA

•

SDS-PAGE and western blotting to visualize the knockdown of the protein

Suggestions for future successful RNAi experiments,
•

Microinject worms with dsRNA (Protocol: (71, 116))

•

Soak worms in dsRNA (Protocol: (71, 116))

Longevity assays were initially conducted in liquid media using 96 well microtiter
plates as described before (97). However, this experiment was not successful. Bacteria
settled to the bottom of the well, which resulted scattering of light (from the microscope
light source to the objective lens) in the turbid medium making it hard to count the number
of worms in each well. My suggestion for this experiment is to shake the microtiter plate
on a microtiter plate shaker for at least 2-3 minutes before counting as mentioned in the
protocol (97). However, our lab did not have a microtiter plate shaker. Therefore, I
conducted the longevity assay in solid media as previously described (117). Measuring
longevity in liquid media is an easy and efficient method to count a large number of worms
compared to solid media. As in solid media worms need to be transferred to new plates
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frequently whereas in this method, worm stay in the same 96 well plate throughout the
experiment.
The observed similar longevity in wild-type and gcp-2 mutants may be due to either
cGCPII not playing a role in ageing or functional complementation by one gcp-2 paralog
for the loss of another gcp-2 paralog in C. elegans as reported ( 113, 114).
2. 7 Conclusions

Taken together, this chapter shows that gcp-2 paralogs play a role in the reproductive
and physiological biology at different levels in C. elegans. However, the underpinning
mechanism is still unclear. The next chapter will focus on understanding underlying
mechanism of cGCPII in the physiological parameter of C. elegans.
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Chapter 3: Investigation of the Role of GCPII in Folate Metabolism
3.1 Introduction

The terminology "folate " is a generic name for a group of chemically associated
compounds based on its structure. Folate or vitamin B9 is a water-soluble B vitamin whose
canonical role is in one-carbon transfer for the de nova synthesis of thymidine, purines,
methionine, and the methyl donor S-adenosylmethionine (118, 119). Animals cannot
synthesize folates and must be assimilated either through diet or food supplementation,
whereas bacteria, fungi, algae and plants synthesize fol ates de nm•o ( 120). Dietary
folates are naturally present in foods such as leafy green vegetables, legumes, egg yolk,
liver, citrus fruit, meat, poultry and fish (118, 121). Folic acid (pteroylmonoglutamic acid)
is the synthetic form which is found in dietary supplements and fortified foods (122).
Dietary folates and folic acid are not metabolically active until they are reduced to various
forms of dihydro (DHF)- or tetrahydrofolates (THF) (118). These reduced forms of folates
are an essential cofactor for one carbon metabolic pathways and thereby, required for the
biosynthesis of a range of cellular components in all prokaryotic and eukaryotic cells (123).

3.2 Chemistry and Stability

Folate is composed of three moieties: a pterine ring (pte), a para-aminobenzoate
(pABA) and one or more glutamates. These terminal glutamate residues are in y-linkages
(Figure 25A). Folates forms vary from each other by: (1) the oxidation states of the
pteridine ring, i.e., dihydrofolate or tetrahydrofolate; (2) modification of the N 5 and/or N 10
positions of the pteridine ring by substitution with formate (5-formyl-THF (aka as folinic
acid), 10-formyl-THF, and 5, 10-methenyl-THF), formaldehyde (5, 10-methylene-THF), or

84

methanol ( 5-methyl-THF) (Table 5); and (3) the number of terminal glutamate residues.
The three forms of formylated-THFs are interconvertible at different conditions. For
example, 5, 10-methenyl-THF is stable at pH 1.5-2.6, and at pH 4.0-5.5 it is converted to
5-formyl-THF. In neural and higher pH, it is converted to 10-formyl-THF and vice versa
(119).
Folates are soluble in alkaline solutions due to the polar hydrophilic character of
the a-carboxyl group. The presence of additional ionizable a-carboxyl groups in
polyglutamated folates makes it more anionic than monoglutamated folic acid. Therefore,
folates with long polyglutamated tail are more hydrophobic compared to shorter tail as the
a-carboxyl groups are highly protonated at lower pH. In neutral pH 5-Formyl-THF is
stable. In acidic pH with heating, it is converted to 5,10-methenyl-THF. The synthetic folic
acid is more stable than dietary folates at different temperatures. For example, folic acid is
stable in 100 °C at pH 5.0-12.0 (121).
The number of terminal glutamate residues does not affect the folate stability.
Oxidative cleavage of the C9 and NlO bonds results in loss of biological activity. Reducing
agents such as ascorbic acid, 2-mercaptoethanol and dithiothreitol can be used to stabilize
folates. The quantity of oxygen and exposure to light have an inverse relationship with
folate stability i.e. higher levels of oxygen reduces the stability. Therefore, the optimal
condition folates are where there is a minimal amount of oxygen and light in higher pH
(121).
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Figure 25. Chemical structure of Folates.
(A) Structure of polyglutamated THF. Red arrows indicate positions of one-carbon groups.

NS and N 10 represent various one-carbon substituents. (B-G) Chemical structure of
different forms of folates. Glun indicates one or more glutamate residues (l 19).
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Table 5. Substituents carried by a THF molecule.
Folate form

Ns a

NI Oa

Figure b

Tetrahydrofolate

-H

-H

B

5-Methyltetrahydrofolate

-CH3

-H

c

5-Formyletrahydrofolate

-CHO

-H

D

10-Formyletrahydrofolate

-H

-CHO

E

5, 10-Metheny ltetrahydrofolate

-CH=N+

-CH=N+

F

5, 10-Methy lenetetrahydrofolate

-CH2-

-CH2

G

a Refer to Figure 25 A
b

Refer to Figure 25B-G

3.3 Biosynthesis in Bacteria
Folates are synthesized de nova in plants, fungi, certain protozoa, and several
archaea and bacteria (124 ). As mentioned in the Section 3 .1 , folate is composed of three
moieties: a pterine ring, pABA and one or more glutamates. Therefore, de nova synthesis
requires 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) and pABA as
precursors.
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Figure 26. Pathway of de novo bacterial biosynthesis of folate.
Sulfamethoxazole and Trimethoprim inhibits folate synthesis. Abbreviations: EPSP, 3enolpyruvylshikimic acid 3-phosphate; GTP, guanosine triphosphate; DHP, 7,8dihydropteroate; DHPPP, 6-hydroxymethyl-7,8-dihydropterin pyrophosphate; pABA,
para-aminobenzoic acid; ATP, Adenosine triphosphate; NADPH, Nicotinamide Adenide
Dinucleotide Phosphate.

PABA (vitamin B10) and aromatic amino acids are produced from the shikimate

pathway (Figure 26) which is employed by microorganisms and plants only and not by
animals (125). Thus, animals need to acquire folates through their diet or gut microbes.
The shikimate pathway initiates by pairing phosphoenolpyruvate (from glycolysis) and Derythrose-4-phosphate (from pentose phosphate pathway). Phosphoenolpyruvate combines
with Shikimic acid through an addition-elimination reaction giving 3-enolpyruvylshikimic
acid 3-phosphate (EPSP). EPSP is transformed to chorismic acid by eliminating 1,4phosphoric acid. Chorismic acid is aminated at C-4 to give 4-amino-4-deoxychorismic acid
by aminodeoxychorismate synthase. Subsequently, pyruvate is cleaved by 4-amino-4deoxychorismate lyase to give pABA (124, 125).
DHPPP is produced by guanosine triphosphate (GTP) in four consecutive steps
(Figure 26). First, GTP is transformed to form a pterin ring structure via Amadori
rearrangement followed by dephosphorylation, aldolase and pyrophosphokinase reactions
ultimately leading to active pyrophosphorylated DHPPP (124). DHPPP and pABA is
coupled by dihydropteroate synthase forming a C-N bond. This condensation reaction
produces 7,8-dihydropteroate (DHP). Dihydrofolate (DHF) is produced from DHP by
incorporating L-glutamate and reduction by DHF reductase yields tetrahydrofolate (THF).
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Addition of multiple glutamate moieties by folylpolyglutamate synthase leads to
polyglutamated THF. Polyglutamylation can occur before the reduction step by DHF
synthase (124, 125). Plants and other microorganisms has the same general biosynthetic
pathway with slight modifications (126).

3.4 Intestinal Absorption

Firstly, dietary polyglutamated-folates are hydrolyzed to monoglutamated folates
by GCPII as folate carriers (discussed later) that transport folates across the mucosa!
membrane are highly specific to monoglutamated folates. GCPII mediated folate
hydrolysis occur at surface of the jejuna! brush border membrane. The optimal pH for this
reaction is 6.5. As discussed in the chapter 1.2, like in NAAG, GCPII cleaves terminal ylinked glutamate residues of folate molecule yielding monoglutamated folates and free
glutamates (Figure 27) (127).
Secondly, the monoglutamated folates are absorbed into enterocytes (intestinal
epithelial cells) via three major genetically distinct and functionally diverse folate transport
systems: reduced folate carriers (RFC), proton-coupled folate transporters (PCFT) and
folate receptors (FR) (128). These carriers absorb monoglutamated-folates within the low
pH (acidic) microenvironment in the duodenum and jejunum, thus, absorption negatively
correlate with pH i.e. lower the pH, higher the affinity ofreceptors for folates (127).
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RFC has high affinity for reduced folate forms : 5-methyl-THF and 5-formyl-THF.
It has approximately - 100-fold lower affinity for synthetic folic acid. RFC is an active

anionic exchanger that counter-transport folates with organic anions. This is the main
transport system for reduced folates in mammalian cells. Human RFC are expressed in
small intestine, colon, placenta, liver, kidney, lung, bone marrow, brain, hepatocyte
membranes, choroid plexus (a branching network of cells that produce cerebrospinal fluid) ,
renal tubular epithelium, and cells lining the spinal canal. Thus, RFC transport folates from
the intestinal lumen to enterocytes, which is then transported through blood to peripheral
tissues as shown in Figure 28 (128).
PCFT is expressed in the duodenum and proximal jejunum, and primarily involved
in folate absorption in the intestine. It is a proton-folate symporter, which couple protons
down an electrochemical gradient to the uptake of different forms of folates into
enterocytes ( 128).
FR has high affinity for folic acid, reduced folates, and folate conjugates. FR
transports folate across the cell membrane by endocytosis. When folates bind to FR at the
cell surface, cytoplasmic vesicles form which releases bound folates to the cytoplasm upon
endosomal acidification. It is present in choroid plexus, retina, kidney, uterus, placenta,
bone marrow, blood cells and adenocarcinomas. Therefore, FR are involved in folate
transport from blood to peripheral tissues (128).
Upon absorption, enterocytes metabolize all different folates to 5-Methyl-THF as
shown in Figure 28. However, this metabolization is limited in folic acid. Metabolized 5Methyl-THF and folic acid are transported out into the hepatic portal vein to hepatocytes
(liver cells) ( 129-131 ). The mechanism by which folates are transported into the hepatic
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portal vein is still not clear. But there are evidences that multidrug resistance proteins-3
(MRP3) expressed at the basolateral membrane of enterocytes is involved this transport
process (130).
Monoglutamated folates, primarily monoglutamated methyl-THF from hepatic
portal vein are actively transported via PCFT expressed on across the cell membrane of
hepatocytes (129). In order to retain folates within the hepatocytes monoglutamated folates
are converted to polyglutamated folates by folate polyglutamate synthetase (FPGS). This
weakens their affinity for folate transporters, thus, can be stored (132).
y-Glutamyl hydrolase (GGH) possesses similar enzymatic activity as GCPII. It is
expressed in the tissues that store high levels of polyglutamated folates like liver and
kidney. GGH is essential to ensure that stored polyglutamated folates are converted to
folate monoglutamates when needed. This strengthens their affinity for folate transporters,
thus, can be transported out of the stored sites to meet systemic folate needs. This enzyme
is localized within lysosome and the optimal pH for this reaction is acidic at 4.5-6.0 (127).
In addition to dietary folates, gut microbes in the colon also produces folates. This
is absorbed by PCFT in the colon. However, the colon pH (6-7) is not favorable for this
process. Therefore, the rate of absorption is less compared to the duodenum and jejunum.
Folates produced by the gut microbes are polyglutamated and terminal glutamate residues
are cleaved by GCPII (Figure 27). Monoglutamated folates are then absorbed by a similar
pathway as dietary folates as shown in Figure 28 (127).
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Figure 28. Folate absorption from intestinal lumen, metabolism in enterocytes, and
transportation out into the hepatic portal vein as 5-Methyl-THF.
PCTF, proton-coupled folate transporter; GCPII, glutamate carboxypeptidase II; RFC,
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3.5 Metabolism
Monoglutamated folates (primarily 5-methyl-THF and folic acids) are released into
the circulatory system from store sites such as liver. This is then taken up by cells via folate
transporters (RFC and FR) and converted to folate polyglutamates by folate polyglutamate
synthetase (FPGS) to retain within the cell (I3 I- 133). These folate molecules act as one
carbon (1 C/methyl groups) units for several biosynthetic processes including pyrimidine,
purine and thymidine synthesis and homocysteine remethylation. This pathway is known
as " IC metabolism" and shown in Figure 29.
One-carbon units are covalently attached to N 5 position and N 10 position of the
pteridine ring and pABA respectively (Figure 25A) and can be held in three different
carbon oxidation states. Firstly, a carbon unit from amino acid serine or glycine is
transferred to THF to form 5,10-methylene-THF. Afterward, this IC unit can be
interconverted between different carbon oxidation states: 5, I 0-methylene--THF, 5-methylTHF, and IO-formyl-THF. Each of this oxidation state supports distinct biosynthetic
functions . Folates loaded with IC units does not cross membranes, thus, produced in both
the mitochondria and cytosol (Figure 29) (132).
As shown in Figure 29, 5,10-methylene-THF can be used in four ways. First it is
used synthesize thymidine. Secondly, when 5, 10-methy lene-THF is oxidized to I 0-formylTHF, it is used to synthesize purines. Thirdly, 5, I 0-methy Jene-THF can provide a carbon
group for the pyrimidine biosynthesis when oxidized to DHF (134, I 35). These are building
blocks of RNA and DNA. Finally, when it is reduced to 5-methyl-THF, can be utilized to
methylate homocysteine to form methionine. Methionine is then converted to S-
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adenosylmethionine (SAM) which is a methyl group donor. This process methylate DNA,
RNA, hormones, neurotransmitters, membrane lipids, proteins and others (135).
Ingestion: dietary ~G_c_P_II+J Absorption: dietary t----1~
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Figure 29. Folate-mediated one-carbon metabolism.
FPGS, Folate polyglutamate synthetase; THF, tetrahydrofolate; DHF, dihydrofolate;
DHFR, dihydrofolate reductase; SHMTl/2, serine hydroxymethyl transferase, cytosolic

(I)/ mitochondrial (2); MTHFD2/L, methylenetetrahydrofolate dehydrogenase 2/ 2-like;
MTHFDlL,

monofunctional

methylenetetrahydrofolate

tetrahydrofolate

dehydrogenase;

Bl2,

synthase,
vitamin

Bl2;

MTHFDl,
SAM,

S-

adenosylmethionine; SAH, S-adenosyl homocysteine; TYMS, thymidylate synthetase;
dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate; Glun,
polyglutamated

folates;

Glu 1,

monoglutamated

carboxypeptidase II; GOH, y-Glutamyl hydrolase.

96

folates;

GCPII,

glutamate

3.6 Deficiencies

Folate deficiencies can occur due to multiple reasons such as inadequate dietary
consumption, malabsorption in the gut and consumption of certain drugs: sulfonamides,
aminopterin, methotrexate, pyrimethamine, trimethoprim and triamterene, which act as
folate antagonists (136, 137). Folate deficiencies have long been known to have adverse
effects on health, such as megaloblastic anemia, neuropathy (138), metabolic dysfunction
(139), abnormal red cell precursors in bone marrow (140), neuropsychiatric disorders
(141) heart diseases and cancer (142). Folate deficiency during pregnancy can lead to
severe defects in brain and spine, termed Neural Tube Defects (NTD) and developmental
delay in neonates (142). Low levels of 5-MTHF in the cerebrospinal fluid can lead to
cerebral folate deficiency. This can cause delayed development, with deceleration of head
growth, hypotonia, and ataxia, dyskinesias (choreo-athetosis, hemiballismus), spasticity,
speech difficulties, and epilepsy (143).
In 1992, the U.S. Public Health Service recommended women capable of becoming
pregnant to consume 400 µg of folic acid per day to decrease NTD. In 1998, the U.S.
mandated fortification of enriched cereal grain products with 140 µg of folic acid per 100
g. These interventions reduced the prevalence of NTD cases (144).

3. 7 The Mechanism of Sulfamethoxazole Action
Sulfa drugs are widely used to treat a broad range of bacterial and protozoa!
infections. Most sulfa drugs, including Sulfamethoxazole (SMX) and Sulfasalazine (SSZ)
are close structural analogs of pABA, which exhibit the antimicrobial activity by
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competing with pABA. This forms sulfa drug-pterin adducts instead of pABA-pterin
adducts of dihydrofolate and thereby depletes bacterial cellular folate levels as shown in
Figure 30 (137).
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Figure 30. Sulfamethoxazole (SMX) is a structural analogue for PABA and inhibits
bacterial folate biosynthesis.
3.8 Hypothesis and Objectives
The hypothesis that governs this study is that cGCPII plays an essential role in
folate metabolism of C. elegans. The Chapter 2 focused on understanding the role of
cGCPII and its paralogs in reproduction, aging and development of C. elegans. The two
objectives of this study are (i) to illustrate the function of cGCPII in folate metabolism and
(ii) to understand how altered folate levels affect the reproduction and development of
wild-type and cGCPII mutants. Thirdly, the efficiency of folate supplementation in
reproduction and development in wild-type and cGCPII mutants will be determined. In
order to provide further information into the different forms of folates present in E. coli
OPSO and consumed by C. elegans, NMR and HPLC based method development are
attempted.
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3.9 Materials and Methods
3.9.1 Preparation of NGM Assay Plates
Bacterial Food Source: SMX treated E. coli OPSO
50 µL of bacteria from the frozen stock at -80 °C was inoculated into 100 mL LB
broth containing varied SMX concentrations: 1 µg /mL, 100 µg/mL, 1000 µg/mL and 2000
µg /mL. Then bacteria were incubated overnight at 35 °C and 250 rpm using an incubating
orbital shaker. Obtained bacterial pellet by centrifuging at 3500 rpm for 5 minutes.
Afterwards, removed the supernatant, resuspend bacteria in sterile water. Again,
centrifuged at 3500 rpm for 5 minutes and removed the supernatant to get rid of SMX.
Measured the pellet weight and added sterile water to normalize bacterial concentration to
200 mg/mL. Growth curve for E. coli OP50 is shown in the Appendix 6.

Preparation of NGM Plates
NGM petri dishes were prepared as mentioned in the Section 2.3.2. Plates were
seeded with 100 µL of SMX treated E. coli OP50. For the Folinic acid (5-formyl-THF)
supplementation experiments, prior seeding 10 µL Folinic acid was added to SMX treated
200 mg/ml E. coli OP50.

3.9.2 Brood Size Assay
Brood size assay was conducted as mentioned in the Section 2.3.6. Prior to the
experiments, worms were maintained in the same experimental conditions for at least three
generations. i.e. worms were maintained on SMX-treated bacteria for three generations
before the brood size assay. Two replicates were performed for each experiment. Statistical
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Analysis was conducted using two-sample t-test assuming equal variances. p value < 0.001
considered significant. Error bars represent ± SEM.

3.9.3 Body Length Assay
Body length assay was conducted as mentioned in the Section 2.3 .9. Prior to the
experiments, worms were maintained in the same experimental conditions for at least three
generations. i.e. worms were maintained on SMX-treated bacteria for three generations
before the body length assay. Three replicates were performed for each experiment.
Statistical Analysis was conducted using two-sample t-test assuming equal variances. p
value < 0.001 considered significant. Error bars represent± SEM.

3.9.4 Bacterial Folate Extraction
100 mL of E. coli OP50 was grown for 14 hours at 37

cc at 220 rpm. Bacterial

culture was centrifuge at 5000 rpm for 5 mins and supernatant was discarded. Bacterial
pellet was resuspended in 10 mL extraction buffer, capped, vortexed and flushed with
Nitrogen for 30 s. Samples were sonicated in ice for 20 seconds, cooled tubes on ice 30 s
and repeated for 9 times. Then, flushed with nitrogen for 1 min, boiled in water for 12 min.
Allowed samples cool on ice for 5 min, centrifuged at 9500 rpm for 15 min at 4

cc and

transferred supernatant to a clean tube (Folate Extract 1). Bacterial pellet resuspended in 5
mL extraction buffer, vortexed, flushed with Nitrogen for 30 and rotated for 10 mins.
Sonicated as before for 9 times. Then, flushed with nitrogen for 1 min, boiled in water for
10 min. Allowed samples cool on ice for 5 min, centrifuged at 9500 rpm for 15 min at 4

cc and pooled supernatant with Folate Extract 1. All extracts (supernatant) were filtered
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through Whatman filter Grade No. 4 (20-25 µM). All the samples, extraction buffer,
standard solutions and folate extract were prepared on the day of analysis. All composition
and preparation details of buffers and solutions are given in the Appendix 4.

3.9.5 Bacterial Folate Extract Purification
Bacterial folate extracts were purified usmg Q Sepharose XL strong anion
exchanger (GE Healthcare) and 0.1 M, 0.5 Mand 1 M phosphate buffers. The purification
steps are elaborated in the Figure 31.
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Figure 31. Bacterial Folate Purification Steps.
KHP04, potassium phosphate buffer; Sample, bacterial folate extract; F 1, flow 1; F2, flow
2; E 1, elution 1; E2, elution 2.
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3.9.6 Folate Standard Preparation
Standards Used: Folinic acid calcium salt hydrate 98% (Alfa Aesar™),

Dihydrofolic acid
~88%

~90%

(Sigma-Aldrich), 5-Methyltetrahydrofolic acid disodium salt

(Sigma-Aldrich) and Tetrahydrofolic acid ~65% (Sigma-Aldrich).
Standard Preparation: The standards were dissolved under subdued light (in a

room with lights tuned off) immediately before analysis in the extraction buffer containing:
O. lM phosphate buffer (pH 6.1 ), with 2% sodium ascorbate (w/v) and 0.1 % 2-

mercaptoethanol (v/v). All samples and buffers were prepared using HPLC grade water
(Fisher Chemical) and filtered through non-sterile 0.2 µm Whatman filter.

3.9. 7 NMR Based Folate Analysis

1 mL of bacterial folate extract without SMX and 100 mg/mL folic acid dissolved
in extraction buffer were added to petri dishes and stored in an oven set to 37 °C for

~5

hours to get rid of extraction buffer. Once samples are completely dried 1 mL of DMSO
was added and swirled until dissolved. Samples were analyzed using 1H NMR. The NMR
experimental conditions are given in the Appendix 5.

3.9.8 HPLC Based Folate Analysis

Analyses of bacterial folate extracts, and folate standards were performed using an
HPLC system (Hitachi Chromaster) consisting of a gradient quaternary pump (5110), an
autosampler (5210), a thermostated column compartment (5310), a diode array detector
(DAD-5430), and a fluorescence detector (5440). The HPLC system was controlled by a
personal computer running software (Chromaster System Manager) . The separation of
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folates was performed on a Thermo Scientific™ Hypersil™ ODS C18 analytical column,
5 µm x 4.6 mm x 200 mm, with a guard column (Thermo Scientific™).
The flow rate was 0.8 mL/min and the temperature of thermostated column
compartment was set to 4 °C. Injection volume was 10 µL. Two Buffers were used for
analysis: Buffer A (IL), 28 mmol dibasic potassium phosphate and 60 mmol phosphoric
acid in water; Buffer B (lL), 28 mmol dibasic potassium phosphate and 60 mmol
phosphoric acid in 200 mL acetonitrile and 800 mL water. The mobile phase program
consisted of 3 min with 100% A, 10 min with 70% A:30% B, 17 min with 45% A:55% B,
15 min with 43% A:57% B followed by 10 min with 100% A and another sample analysis
began immediately. The florescence intensity of standards and folate extracts monitored
with a fluorescence detector (excitation at 295 nm and emission at 360 nm). Peaks were
identified on the basis of the retention time folate standards.
HPLC

program

was

stored

at

Folate_DAD_Hypersil_ODS_Gra.
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3.10 Results
3.10.1 The Effect of Reduced Dietary Folates on Reproduction
In order to determine the effect of GCPII dependent folate metabolism

on

reproduction and brood size assays were conducted in wild-type and gcp-2 mutant worm
strains that were maintained on E. coli OP50 with various concentrations of SMX for at
least three generations. As mentioned in the Section 3.7, SMX inhibits folate biosynthesis
and the level of inhibition increases with increasing concentration of SMX (105 , 106).
Thus, the available amount of folate and its derivatives reduces with increasing SMX used
in treating the bacterial food. This allows to investigate the effect of reduced dietary folate
levels on C elegans. Reproduction was quantified as brood size and the data shown are
representative of 2 biological replicates with 5 worms each.
As shown in the Figure 32, wild-type worms showed a concentration dependent decline in
brood size. The average brood size without SMX was 283 .11 (±3.8) whereas when the
worms consumed bacteria treated various concentrations of SMA were as follows:

1

µg/mL SMX - 272.5 (±6.5); 100 µg /mL, 178.7 (±6.7); 1000 µg /mL, 81.2 (±8.1) and 2000
µg /mL, 1.33 (±2.5). There was not a significant difference at 1 µg/mL (p>0.001) compared
to untreated control. However, there was a significant (p<0.001) decline in brood size at
100 µg /mL, 1000 µg /mL and 2000 µg/mL SMX. Therefore, SMX resulted 3. 7%, and
36.8% decline in progeny production at 1 µg /mL and 100 µg/mL, respectively. At the half
maximal inhibitory concentration (IC,., = 1025 µg /ml) of SMX, 71.3% drop in progeny
production was shown and at twice the IC,., of SMX, 99.9% decline in progeny production
was observed. Hence, data indicates that the reproduction of wild-type worms were
affected by SMX induced folate synthesis inhibition in a concentration dependent manner.
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Figure 32. The effect of SMX dependent folate inhibition on brood size of wild-type

C.elegans.
The mean brood size of control (no SMX), 283.1. The mean brood size of worms
maintained on E. coli treated with 1 µg/mL , 272.5 (p=0.09); 100 µg /mL, 178.7 (p=
3.87094E-11); 1000 µg /mL, 81.2 (p=4.47966E-20) and 2000 µg /mL, 1.33 (p= 1.28891E22). Statistical significance was determined using two sample T-test (*p > 0.001 , **p <
0.001). **p < 0.001 considered significant. The error bars represent± SEM. Data shown
are representative of two biological replicates of five worms each.
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Similarly, gcp-2.1 mutant worms showed a concentration dependent decline in
brood size (Figure 33). The average brood size without SMX was 242.5 (±4.3) and when
the worms consumed bacteria treated various concentrations of SMA the brood size
measurements were as follows : 1 µg /mL SMX, 247.4 (±9); 100 µg/mL, 13.1 (±1.3); 1000
µg/mL, 2.9 (±0.4) and 2000 µg /mL, 0.8 (±0.4). There was not a significant difference at 1
µg /mL (p>0.001) compared to non-treated control. However, there was a significant
(p<0.001) decline in brood size at 100 µg /mL, 1000 µg/mL and 2000 µg /mL SMX.
Therefore, SMX resulted 94.5% decline in progeny production at 100 µg /mL. At IC,. and
twice the IC,. concentrations of SMX, there was a 99.9% drop in progeny production.
Hence, data indicate that the reproduction of gcp-2. 1 mutants were affected by SMX
induced folate inhibition in a concentration dependent pattern. Furthermore, the data
indicate that the reduction in brood size severe in gcp-2. 1 mutant compared to the wild type
at same concentrations of SMX.
As shown in Figure 34, gcp-2.2 mutant worms also showed a similar concentration
dependent decline in brood size as seen in gcp-2.1 mutant. The average brood size without
SMX was 238.6 (±5.5) and when the worms consumed bacteria treated various
concentrations of SMA the brood size measurements were as follows : 1 µg/mL SMX,
235 .3 (±3.5). There was not a significant difference at 1 µg/mL (p>0.001) compared to
non-treated control. Interestingly, in contrast to gcp-2.1 , gcp-2.2 mutants were sterile at
100, 1000 and 2000 µg /mL SMX. In the 2"d and 3rd generations at 100 and 1000 µg /mL
SMX, worms laid eggs as shown in Figure 36, however, only few eggs hatched. An attempt
to obtain an age synchronized population using these eggs to conduct the brood size assay
failed as eggs did not survive after treating with bleach. In addition, at twice the IC,. (2000

106

µg /mL) of SMX was lethal to the test worms (all the worms were dead after few days).
Hence, data indicates that the reproduction of gcp-2.2 mutants were intensely affected by
SMX induced folate inhibition in a concentration dependent pattern. It is important to note
that at 2000 µg /mL of SMX both wild type and gcp-2. I mutant survived and laid eggs.
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Figure 33. The effect of SMX dependent folate inhibition on brood size of gcp-2.1
mutant C. elegans.
The mean brood size of control (no SMX), 242.5.

The mean brood size of worms

maintained on E. coli treated with 1 µg /mL, 247.4 (p= 0.316); 100 µg/mL , 13.1 (p= 3
3.80069E-21); 1000 µg/mL, 2.9 (p= 8.93304E-22) and 2000 µg /mL, 0.8 (p= 7.43351E-22).
Statistical significance was determined using two sample T-test (*p > 0.001 , **p < 0.001).
**p < 0.001 considered significant. The error bars represent ± SEM. Data shown are
representative of two biological replicates of five worms each.
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Figure 34. The effect of SMX dependent folate inhibition on brood size of gcp-2.2
mutant C.elegans.
The mean brood size of control (no SMX), 238.6. The mean brood size of worms
maintained on E. coli treated with 1 µg/mL, 235.3 (p= 0.31196332). Worms did not
reproduce at 100, 1000 and 2000 µg/mL (p= 7.60113E-20). Statistical significance was
determined using two sample T-test (*p > 0.001 , **p < 0.001). **p < 0.001 considered
significant. The error bars represent ± SEM. Data shown are representative of two
biological replicates of five worms each.
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As shown in the Figure 35, gcp-2.3 mutants showed a concentration dependent
decline in brood size in. The average brood size without SMX was 249.8 (±5.8) and when
the worms consumed bacteria treated various concentrations of SMA the brood size
measurements were as follows: 1 µg/mL SMX, 252.89 (±4.4); 100 µg/mL, 188.1 (±7.6);
1000 µg /mL, 43.7 (±5.5) and 2000 µg/mL, 3 (±0.6). There was not a significant difference
at 1 µg/mL (p>0.001) compared to non-treated controls. However, there was a significant
(p<0.001) decline in brood size at 100 µg /mL, 1000 µg/mL and 2000 µg /mL SMX.
Therefore, SMX resulted 24.6% decline in progeny production at 100 µg /mL. At IC,. of
SMX, 82.5% drop in progeny production was shown and at twice the IC.. of SMX, 98.8%
decline in progeny production was observed. Hence, data indicates that the reproduction of
gcp-2.3 mutants were affected by SMX induced folate inhibition in a concentration

dependent manner. However, the relative progeny production is higher than gcp-2.1 and
gcp-2.2 as shown in Figure 36.

The Figure 36 shows the images of growth phenotype of the wild-type and gcp-2
mutant C. elegans maintained on 1000 µg/mL SMX treated E. coli OP50. These images
displays how SMX induced folate inhibition affected the wild-type and gcp-2 mutants
differently. The NGM plates withgcp-2.1 and gcp-2.2 worms were drastically less crowded
compared to wild-type and gcp-2.3 mutants. The NGM plate with wild-type was the most
crowded and contained a lot of gravid adults, eggs and L-L2 worms. The NGM plate with
gcp-2.2 mutants was the least crowded plate with few worms and eggs which did not

develop into Ll larva. Taken together, wild-type and all gcp-2 mutant strains were affected
by SMX induced folate inhibition in a concentration dependent manner. gcp-2.1 and gcp2. 2 mutants were affected to higher extent compared to the wild-type and gcp-2.1 mutants.
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Figure 35. The effect of SMX dependent folate inhibition on brood size of gcp-2.3
mutant C. elegans.
The mean brood size of control (no SMX), 249.8. The mean brood size of worms
maintained on E. coli treated with 1 µg /mL, 252.89 (p= 0.34); 100 µg /mL, 188.1 (p=
2.54803E-06); 1000 µg/mL, 43.7 (p= 6.74562E-16) and 2000 µg/mL, 3 (p= 9.85037E-20).
Statistical significance was determined using two sample T-test (*p > 0.001 , **p < 0.001).
**p < 0.001 considered significant. The error bars represent ± SEM. Data shown are
representative of two biological replicates of five worms each.
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Figure 36. Growth assay showing growth phenotype of the wild-type and gcp-2
mutants. C.elegans were maintained on 1000 µg /mL SMX treated E. coli OPSO.
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3.10.2 The Effect of Reduced Dietary Folates on Development
In order to determine the effect of GCPII dependent folate metabolism on overall
physiology and body development, body length assay was conducted in wild-type and gcp2 mutants maintained on E. coli OP50 grown with various concentrations of SMX. As

mentioned in the Section 3.7, SMX inhibits folate biosynthesis and the synthesis of folates
reduces with increasing SMX. This allows to investigate the effect of reduced dietary folate
levels on C elegans. Development was quantified as body length and the data shown are
representative of three biological replicates of 3-5 worms each.
As shown in the Figure 37, the body length of wild-type worms was not affected
by the varying concentrations of SMX. The average body length without SMX was 31.1
whereas when consumed on bacteria treated with 1 µg /mL SMX, 31.9; 100 µg/mL, 27.7;
and 1000 µg /rnL, 30. Therefore, there was not a statistically significant (p>0.001) body
length change at the tested concentrations of 1 µg/rnL, 100 µg /rnL and 1000 µg /rnL
compared to that of the untreated control. The body length images of the wild-type worms
at different SMX concentrations is shown in the Figure 38 which displays similar body
length at various SMX concentrations.
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Figure 37. The effect of SMX dependent folate inhibition on body length of wildtype C. elegans.
The mean body length of control (no SMX), 31.1 . The mean body length of worms
maintained on E. coli treated with I µg/mL, 31.9 (p= 0.04 ); I 00 µg/mL, 27. 7 (p= 0.0075);
and I 000 µg/mL , 30 (p= 0.175616667). Statistical significance was determined using two
sample T-test (*p > 0.001, **p < 0.001). **p < 0.001 considered significant. The error bars
represent± SEM. Data shown are representative of three biological replicates 3-5 worms
each.
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Figure 38. The images of wild-type worms at different concentrations of SMX.
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As shown in the Figure 39, the body length of gcp-2.1 worms were affected by the
varying concentrations of SMX. The average body length without SMX was 37.4 (±)
whereas when consumed on bacteria treated SMX showed the following body lengths: 1
µg/mL SMX, 29.2 (±); 100 µg/mL, 27 (±); and 1000 µg /mL, 24.89 (±). There was a
statistically significant (p<0.001) decline in body length at 1 µg/mL, 100 µg/mL and 1000
µg/mL SMX compared to untreated worms. Therefore, SMX resulted 21 .9% and 27%
decline in body length at 1 µg /mL and 100 µg /mL, respectively. At the IC,. concentration
of SMX, 33 .4% drop in body length was observed. The body length images of the gcp-2.1
worms at different SMX concentrations is shown in the Figure 40. Furthermore, the worms
that consumed SMX treated OP50 not only had shortened body length but also their body
width was significantly reduced with increasing SMX concentrations, resulting in overall
small sized worms compared to the control as visible from the Figure 40. Hence, data
indicate that the development of gcp-2.1 mutant worms were affected by SMX induced
folate inhibition in a concentration dependent manner.
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Figure 39. The effect of SMX dependent folate inhibition on body length of gcp-2.1
mutant C.elegans.
The mean body length of control (no SMX), 37.4. The mean body length of worms
maintained on E. coli treated with I µg/mL, 29.2 (p= l.35244E-08); 100 µg/mL, 27 (p=
8.8024E-08); and 1000 µg/mL , 24.89 (p= 9.6054E-l 0). Statistical significance was

determined using two sample T-test (*p > 0.001, **p < 0.001). **p < 0.001 considered
significant. The error bars represent ± SEM. Data shown are representative of three
biological replicates 3-5 worms each.
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Figure 40. The images of gcp-2.1 mutants at different concentrations of SMX.
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As shown in the Figure 41 , the body length of gcp-2. 2 worms were affected by the
varying concentrations of SMX. The average body length without SMX was 43 .1 (±)
whereas when consumed on bacteria treated with SMX the body lengths were as follows :
1 µg/mL SMX, 34.9 (±); 100 µg/mL, 32.6 (±); and 1000 µg/mL, 36.6 (±). There was a
statistically significant (p<0.001) decline in body length at 1 µg/mL, 100 µg /mL and 1000
µg /mL SMX. Therefore, SMX resulted 19% and 24.3% decline in body length at 1 µg /mL
and 100 µg /mL, respectively. At the IC,. concentration of SMX, 15% drop in body length
was observed. The body length images of the gcp-2.2 worms at different SMX
concentrations is shown in the Figure 42. This displays the shortening of body length with
SMX compared to the untreated control and body width was similar. Although, the
development of worms was affected by SMX, there was not a significant variation among
different concentrations. Hence, data indicates that the development of gcp-2. 2 mutant
worms were affected by SMX induced folate inhibition in but not in a concentration
dependent pattern.
As shown in the Figure 43 , the body length of gcp-2.3 worms were affected by
SMX. The average body length without SMX was 28.2 (±)whereas when consumed on
bacteria treated with SMX showed the following body lengths: 1 µg/mL SMX, 30.8 (±);
100 µg/mL, 27.4 (±);and 1000 µg /mL, 20.7 (±). There was not a statistically significant
(p>0.001) decline in body length at 1 µg /mL, and 100 µg /mL. However, at the IC.
concentration of SMX (1000 µg/mL) SMX, 26.6% drop in body length was observed.
Hence, data indicates that the development of gcp-2.3 mutant worms were affected by
SMX induced folate inhibition at higher concentrations of SMX.
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Taken together, the development of wild-type and gcp-2.3 mutant strains were not
affected by SMX whereas the development of gcp-2.1 and gcp-2.2 mutants affected by
SMX induced folate inhibition.
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Figure 41. The effect of SMX dependent folate inhibition on body length of gcp-2.2
mutant C.elegans.

The mean body length of control (no SMX), 43.1. The mean body length of worms
maintained on E. coli treated with I µg/mL, 34.9. (p= 2.36531 E-07); I 00 µg/mL, 32.6 (p=
2.58029E-06); and I 000 µg/mL, 36.6 (p= 0.00036). Statistical significance was determined
using two sample T-test (*p > 0.001, **p < 0.00 I). **p < 0.001 considered significant. The
error bars represent± SEM. Data shown are representative of three biological replicates 35 worms each.
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Figure 42. The images of gcp-2.2 mutants at different concentrations of SMX
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Figure 43. The effect of SMX dependent folate inhibition on body length of gcp-2.3
mutant C. e/egans.
The mean body length of control (no SMX), 28.2. The mean body length of worms
maintained on E. coli treated with 1 µg/mL, 30.8 (p= 0.01 ); 100 µg/mL, 27.4 (p= 0.091 );
and 1000 µg /mL, 20.7 (p= 1.9501 E-11 ). Statistical significance was determined using two
sample T-test (*p > 0.00 l, **p < 0.00 l ). **p < 0.001 considered significant. The error bars
represent ± SEM. Data shown are representative of three biological replicates 3-5 worms
each.
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3.10.3 The Effect of Folinic Acid (5-Formyl-THF) Supplementation

Folinic acid, 5-Formyl-THF, is an important folate derivative that can be
transformed into other folate derivatives as shown in Figure 28. I hypothesize that
supplementation of SMX treated OP50 food is expected to reverse the effects of SMXmediated folate availability on brood size and body lengths. In order to determine the effect
of folinic acid supplementation on GCPII dependent folate metabolism on reproduction,
brood size assays were conducted in wild-type and gcp-2 mutants maintained on E. coli
OP50 grown with 1000 µg /mL of SMX and supplemented with 10 µM Folinic acid. This
concentration of Folinic acid was used as it was previously reported to reverse the effects
of folate inhibition in body length (106). This allows to investigate the efficacy of folate
supplementation on folate deficient C. elegans-E. coli model. Reproduction was quantified
as progeny size and the data shown are representative of one biological replicate with five
worms.
The effect of folinic acid supplementation in reversing the effects of 1000 µg /mL
SMX induced folate inhibition was shown in the Figure 44. The mean brood size of wildtype without supplementation, 81.2 (±3.9) and with supplementation, 105 (±2.5). This is
a 29% increase in reproduction and statistically significant (p<0.001). The mean brood size
of gcp-2.1 without supplementation, 2.9 (±0.4) and with supplementation, 2.7 (±0.4),
showing no statistically significant (p>0.001) effect in reproduction. The gcp-2.2 were
sterile without supplementation and with supplementation worms were slightly fertile with
an average brood size of 2.2 (±0.5). This is a statistically significant (p<0.001) increase in
reproduction. The mean brood size of gcp-2.3 without supplementation, 43.7 (±2.4) and
with supplementation, 44.8 (±5.5). Therefore, there is no statistically significant (p>0.001)
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Figure 44. The effect of Folinic Acid supplementation on brood size of C. elegans
that were supplied with 1000 µg/mL SMX treated OP50 as food.
The

mean

brood size of wild-type without supplementation,

81 .2 and

with

supplementation, 105 (p=3.7996E-05). The mean brood size of gcp-2.1 mutants without
supplementation, 2.9 and with supplementation, 2.7 (p= 0.39). The mean brood size of gcp-

2.2 mutants without supplementation, sterile and with supplementation, 2.2 (p= 0.0008).
The mean brood size of gcp-2.3 without supplementation, 43.7 and with supplementation,
44.8 (p= 0.429). Statistical significance was determined using two sample T-test (*p >
0.001 , **p < 0.001). **p < 0.001 considered significant. The error bars represent± SEM.
Data shown are representative of one biological replicate with 5 worms.
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effect in reproduction. Hence, folinic acid supplementation was effective in reversing the
effect of SMX induced folate inhibition on reproduction of wild-type and to some extent
in gcp -2.2 worms but not gcp-2.1 and gcp-2.3 mutants.
In order to determine the effect of folinic acid

supplementation on GCPII

dependent folate metabolism on development, body length assay was conducted in wildtype and gcp-2 mutants maintained on E. coli OP50 grown with varying concentrations of
SMX and supplemented with 10 µM Folinic acid. This allows to investigate the efficacy
of folate supplementation on folate deficient C. elegans-E. coli model. Development was
quantified as body length and the data shown are representative of two biological replicates
with five worms each.
The effect of folinic acid supplementation in reversing the developmental effects
of SMX induced folate inhibition was shown in the Figures 47-49. When folinic acid was
supplemented to worms maintained on E. coli without SMX, only wild-type showed
statistically significant (p<0.001) increase in body length which was a 6.5% increase
(Figure 45). When folinic acid was supplemented to worms maintained on E. coli with 100
µg/mL SMX, only gcp-2.2 showed statistically significant (p<0.001) increase in body
length which was a 8.1 % increase. When folinic acid was supplemented to worms
maintained on E. coli with 1000 µg /mL SMX, only gcp-2.2 showed statistically significant
(p<0.001) increase in body length which was a 22.4% increase. Therefore, folinic acid
supplementation induced development of wild-type and gcp-2.2 mutants.
Taken together, folinic acid supplementation was effective in reversing the effect
of SMX induced folate inhibition on reproduction of wild-type worms not gcp-2 mutants.
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Additionally, folinic acid supplementation was effective in reversing the effect of SMX
induced folate inhibition on development of gcp-2.2 mutants.
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Figure 45. The effect of folinic acid supplementation on the body length untreated
controls.
The mean body length of wild-type without supplementation, 30. l and with
supplementation, 32.2 (p= 0.00066). The mean body length of gcp-2.1 mutants without
supplementation, 33.1 and with supplementation, 33 (p= 0.43). The mean body length of

gcp-2.2 mutants without supplementation, 29.9 and with supplementation, 30.8 (p= 0.033).
The mean body length of gcp-2.3 without supplementation, 28.2 and with supplementation,
30. l (p=0.0059). Statistical significance was determined using two sample T-test (*p >
0.001 , **p < 0.00 l ). **p < 0.001 considered significant. The error bars represent± SEM.
Data shown are representative of two biological replicates with 5 worms each.
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Figure 46. The effect of folinic acid supplementation on the body length of worms
maintained on E. coli treated with 100 µg/mL SMX.
The mean body length of wild-type without supplementation, 27 and with supplementation,
29 (p= 0.012). The mean body length of gcp-2.1 mutants without supplementation, 29.4
and with supplementation, 28.7 (p= 0.149). The mean body length of gcp-2.2 mutants
without supplementation, 27 and with supplementation, 29.4 (p= 0.00035). The mean body
length of gcp-2.3 without supplementation, 27.4 and with supplementation, 27.9 (p=
0.1493). Statistical significance was determined using two sample T-test (*p > 0.001 , **p

< 0.001 ). **p < 0.00 l considered significant. The error bars represent± SEM. Data shown
are representative of two biological replicates with 5 worms each.
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Figure 47. The effect of folinic acid supplementation on the body length of worms
maintained on E. coli treated with 1000 µg/mL SMX.
The mean body length of wild-type without supplementation, 23.6 and with
supplementation, 26.7 (0.0016). The mean body length of gcp-2. 1 mutants without
supplementation, 24 and with supplementation, 23.45 (p=0.148). The mean body length of

gcp-2.2 mutants without supplementation, 20.7 and with supplementation, 26.7 (p=
3.22583E-08). The mean body length of gcp-2.3 without supplementation, 20.54 and with
supplementation, 22 (0.0073). Statistical significance was determined using two sample Ttest (*p > 0.001 , **p < 0.001 ). **p < 0.00 I considered significant. The error bars represent
± SEM. Data shown are representative of two biological replicates with 5 worms each.
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3.10.4 Identification and Quantitation of Folate Derivative in E. coli OPSO
In order to further understand the effect of folate derivatives mediated reproductive and
physiological effects on wild type and GCPII mutant C elegans we aimed to identify the
folate derivatives present in the E. coli OP50 food source. In order to identify folate
derivatives both 1H-NMR and HPLC techniques were attempted. For the quantitation of
folate derivatives HPLC methods were used.

NMR Based Folate Analysis
In order to detect different forms of folates present in bacterial folate extract folic
acid standards were analyzed using 1H-NMR. However, this experiment was not successful
in identifying folates as I was not able to detect the distinct peaks that can be assigned to
corresponding to folates unequivocally and therefore further analysis of folate were
conducted using HPLC methods only. NMR spectra are shown the Appendix 4.

3.10.5 HPLC Based Folate Analysis
Analyses of Folate Derivative Standards
Analyses of folate standards were performed using HPLC to identify the peaks
corresponding different forms of folates. All standards were dissolved in extraction buffer
and monitored with a fluorescence detector set to excitation at 295 nm and emission at 360
nm. The peaks of each folate standard are shown in the Table 6.

Folate Extract
Analyses of folate extracts from E. coli OP50 were performed using HPLC to identify the
different forms of folates present. The absorbance was monitored with a fluorescence
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detector set to excitation at 295 nm and emission at 360 nm. The HPLC spectra for folate
extracts is shown in figure 57. Spectra of bacterial folate extracts showed the peaks for
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Figure 48. Chromatogram with florescence intensity of Extraction buffer without
folates.
The separation of folates was performed using Hypersil ODS C 18 analytical column with
a flow rate of 0.8 mL/min at 4 °C. Intensity was monitored with a fluorescence detector set
to excitation at 295 nm and emission at 360 nm.
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Figure 49. Chromatogram with florescence intensity of DHF standards.
DHF was dissolved in extraction buffer (5 mg/mL). Intensity was monitored with a
fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 50. Chromatogram with florescence intensity of THF standard.
THF was dissolved in extraction buffer (5 mg/mL). Intensity was monitored with a
fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 51. Chromatogram with florescence intensity of 5-Methyl-THF standard.
5-Methyl-THF was dissolved in extraction buffer (25-300 mg/mL). Intensity was
monitored with a fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 52. Chromatogram with florescence intensity of 5-Formyl-THF standard.
5 -Formyl-THF was dissolved in extraction buffer (5-100 mg/mL). Intensity was monitored
with a fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 53. Chromatogram with florescence intensity of Folic Acid standard.
Folic Acid was dissolved in extraction buffer (5-100 mg/mL). Intensity was monitored with
a fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 54. Chromatogram with florescence intensity of L-Glutamic Acid standard.

L-Glutamic acid was dissolved in extraction buffer (10 mg/mL). Intensity was monitored
with a fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 55. Chromatogram with florescence intensity of a mixture of different folate
forms.
This sample contained 5 mg/mL DHF, THF, Folinic acid, Folic acid and 5-Methyl-THF.
All folate derivatives were dissolved in extraction buffer. Intensity was monitored with a
fluorescence detector set to excitation at 295 nm and emission at 360 nm.
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Figure 56. Comparative chromatogram of different folate forms.
This figure contains chromatograms from Figure 48-55
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Figure 57. Overlaid Chromatograms with florescence intensity of E. coli OP50 folate
extracts with varying concentrations of SMX.
Top-full chromatogram; bottom-zoomed in version (15-60 min). All folate extracts were
prepared in extraction buffer. Intensity was monitored with a fluorescence detector set to
excitation at 295 nm and emission at 360 nm. E. coli OP50 folate extracts exhibited peaks
for DHF, THF, 5-Formly-THF, and 5-Methyl-THF.
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Table 6. Fluorescence Detection of Folate Standard.

Compound b

Concentration
(mg/mL)

a

Retention
Time
(min)

E.coli OP50

Peak Height
(intensity)

18.1-22.7

2000

18.12-20.32

2000

29.1-30.29

1197

31.48-37.41

2000

37.51-38.94

1559

42.1-44.46

2000

47.52-49.2

658

52.25-54.9

504

25

44.61-45.8

903

50

44.37-45.7

2000

150

43.6-44.95

2000

200

43.3-44.98

2000

50

20.81-21.26

18.14

200

20.80-21.29

23 .24

5-Formyl-THF

50

37.38-42.85

25

(Folinic acid)

100

37.39-42.91

49

10

37.1-40.57

1012

DHF

THF

5-Methyl-THF

Folic acid

L-Glutamic
acid
a

5

5

Refer to Figure 50-56

c ./,

ct

,j c
,j

,j

ND

ct

,j

ND

All compounds were dissolved in extraction buffer and monitored with a fluorescence

detector (excitation at 295 nm and emission at 360 nm)
b

Extract

detected in E. coli OP50 folate extract

ND, not detected in E. coli OP50 folate extract
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3.11 Discussion

Chapter 2 concludes that mutations in cGCPII and gcp-2 paralogs reduced progeny
production and negatively impacted development of C. elegans to different extents.
However, the underlying mechanism for these observations is unclear. Therefore, Chapter
3 aims to shed light on the predicted multiple biological functions, biochemical
mechanisms and pathways by which cGCPII affects these physiological parameters. In
particular, this chapter focuses on illustrating the function of cGCPII and gcp-2 paralogs
in folate metabolism in regulating reproduction, embryonic and post-embryonic
development of C. elegans.
As shown in the comparative Figure 58, all the gcp-2 mutants show slightly reduced
progeny production compared to wild-type. Furthermore, more strikingly, all strains
showed a concentration dependent decline in brood size i.e. as SMX induced folate
biosynthesis inhibition increases, progeny size decreases. Therefore, the decrease of
reproduction with increasing folate inhibition indicate that there is a link between folate
metabolism and reproduction. Furthermore, the observed differences in progeny
production between wild-type and strains with mutations in gcp-2 paralogs indicate that
cGCPII plays a role in reproduction through regulating folate metabolism.
C. elegans has two putative orthologs to the human reduced folate carrier (hRFC),

referred asfolt-1 andfolt-2. The expression of these genes is regulated during development
and present in different tissues with highest expression levels in pharynx and intestine
(145). FOL T-1 and FOLT-2 exhibits similar characteristics to hRFC such as similar affinity
for oxidized, reduced, and substituted folate derivatives. Furthermore, the amino acid
sequence offolt-1 has high sequential similarity with the substrate binding domains of
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hRFC (145). As mentioned in the Section 3.4, hRFC are highly selective towards
monoglutamated folates. However, whether the folate carriers in C. elegans display similar
selectivity for monoglutamated folates have not yet been reported. Nevertheless, if folt-1
andfolt-2 shows similar functional characteristics and similar protein sequence in substrate

binding domains with hRFC, therefore, it is possible that these transporters could be
selective towards monoglutamated folates. Folate derivatives in E. coli OP50 is produced
as polyglutamates with three to seven glutamate residues ( 119). In those instances, the
hydrolytic enzyme function of GCPII can be vital in cleaving off y-linked glutamates from
polyglutamated folates (Figure 27) in C. elegans. Bases on this information, a hypothetical
model elaborating the mechanism of GCPII in folate metabolism in C. elegans is shown in
the Figure 59. In brief, (i) cGCPII hydrolyzes dietary polyglutamated-folates to
monoglutamated folates in the intestinal lumen, (ii) monoglutamated folates are absorbed
into enterocytes via folate transporters (FOL T-1/FOL T-2) present in the enterocyte
membranes facing the intestinal lumen, (iii) enterocytes metabolize all different folates to
5-Methyl-THF and (iv) Folates are transported out into interstitial space and carried around
the body by the interstitial fluid to be taken up by other cells for one-carbon metabolism
necessary for reproduction, other cellular functions and overall physiology.
Two obvious questions are what happen' s to folates after absorption and how
folates contribute to reproduction? As mentioned in the Section 1.4, C. elegans enterocytes
use absorbed nutrients to synthesise yolk and secrete as free-floating granules into
pseudocoelomic space which is then transported to the oocytes in the proximal gonadal
arm (57, 76, 146, 147). Then yolk material is internalized into maturing oocytes via
receptor-mediated endocytosis and resides in vesicles (148, 149). During embryogenesis,
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yolk granules reside in the blastomeres and C elegans only use this yolk partially. During
morphogenesis the leftover yolk is transferred into the intestinal cells, thus, present in larval
intestines (148-151 ). Mutations in the genes that regulate yolk trafficking and yolk
receptors are lethal suggesting that yolk is essential for embryonic development ( 148). The
exact chemical composition of yolk is not known but it contains vitellogenin proteins and
phospholipids (77, 78). Although folates are not yet reproted in C elegans yolk, in other
organisms such as hens yolk contain 24.8 mcg folates (152). Furthermore, in several
organisms including humans and mice, reduced folate levels during pregnancy is
associated with infertily, NTD's and developmental delay in offspring (Section 3.6). This
shows the importance of folates in embryonic development and reproduction. Folates acts
as an essential co-factor in lC metabolism and vital for purine and pyrimidine synthesis
required for DNA and RNA synthesis, thereby, involved in cell division and repair (Section
3.6), thus, impotant for embryonic development. Previous studies have reprorted that
FOL T-1 and bacterial folates are required to stimulate germline proliferation in isolated C

elegans germ cells in vitro (119). During reproductive life, C.elegans germ line undergo
proliferation and meiotic development to produces gametes (153). Therefore, as folates are
important for gamete production and C elegans germ cells receive nurtrients from the yolk,
this indicates that absorbed folates are stored in yolk and transported into gonads through
body cavity to support gamete production and oocyte embryonic developmment. Thus,
observed decline in brood size of C elegans with increasing folate inhibition is due to
reduction in C elegans germline development.
The Figure 36 with images of growth phenotype displays how SMX induced folate
synthesis inhibition affected the wild-type and gcp-2 mutants differently. The NGM plates
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with gcp-2.1 and gcp-2.2 worms were drastically less crowded compared to wild-type and
gcp-2.3 mutants. The NGM plate with wild-type was the most crowded and contained a lot

of gravid adults, eggs and Ll-L2 worms. The NGM plate with gcp-2.2 mutants was the
least crowded plate with few worms and eggs which did not develop into L 1 larva.
Therefore, observed disparities in reproduction between gcp-2 paralogs indicates that
cGCPII plays a role in reproduction through regulating folate metabolism and each gcp-2
paralog contributes to folate metabolism at different levels. These observed disparities in
reproduction between gcp-2.1, gcp-2.2 and gcp-2.3 mutant strains indicate that cGCPII
each gcp-2 paralog contributes to folate metabolism at different levels. As gcp-2.1 and gcp2.2 mutants were affected to higher extent compared to the wild-type and gcp-2.1 mutants

implies that gcp-2.1

and gcp-2.2 paralogs are more important in folate metabolism

compared to gcp-2.1.
Another important observation is that both gcp-2.1 and gcp-2.2 showed significant
reduction or total abolition of progeny production beyond 100 µg/mL SMX treatment. Both
gcp-2.1 and gcp-2. 2 may not be functional complements in folate metabolism as they failed

to restore each other's role.
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Figure 58. Comparative plot of the effect of SMX dependent folate inhibition on brood
size of wild-type and gcp-2 mutant C.elegans.
Statistical significance was determined using two sample T-test (*p > 0.001, **p < 0.001).
**p < 0.001 considered significant. The error bars represent± SEM.
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Figure 58. Hypothetical model for GCPII dependent folate absorption in C. elegans.
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monoglutamated folates; THF, tetrahydrofolate; 5-Methyl-THF, monoglutamated methylTHF; and Formyl, monoglutamated formyl-THF.
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The body development of wild-type and gcp-2.3 mutant strains were not affected
by folate inhibition whereas the development of gcp-2.1 and gcp-2.2 mutants were affected
by SMX induced folate synthesis inhibition. This suggests that cGCPII dependent folate
metabolism contributes to C elegans development even after hatching i.e. postembryonic.
As mentioned in the Section 1.3.5, C elegans contains only - 550 cells at the end of
embryonic development or when eggs hatch but a gavid adult has 959 cells. Therefore,
cells further divide at postembryonic level. This allows animals to substantially grow
during the larval stages from 550 to 959 cells. Postembryonic development is stimulated
through feeding by pharyngeal pumping. However, it is not clear whether pharyngeal
pumping takes food from outside or from the yolk vesicles within the embryo. The
postembryonic development at larval stages is due to the germ line proliferation and
meiotic development (153). Yolk synthesis starts during L4 lethargus and continues
through the adult life (154). However, as mentioned ealier, during morphogenesis the
leftover yolk is transferred into the intestinal cells, thus, present in larval intestines. This
suggests that yolk is utilized during larval stages to support germ line proliferation and
meiotic development allowing worms grow i.e. to increase in body length.
As the SMX induced retardation in body length was only observed in gcp-2.1 and
gcp-2.2 mutants and not in wild-type and gcp-2.3 mutant strains show that gcp-2.1 and
gcp-2.2 paralogs are more important in folate metabolism compared to gcp-2.3 supporting

the conclusion from reproduction data.
As discussed in results, gcp-2.2 worms with 100 and 1000 µg /mL SMX laid eggs
as shown in Figure 36, however, only few eggs hatched, and most of the eggs did not
develop into L 1 larva. Even in multiple attempts to obtain an age synchronized population,
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these eggs did not survive after treating with bleach (no LI were present after the bleaching
process). These results suggest that there is a link between folate levels, gcp-2.2 and the
development of embryo outside the hermaphrodite. As discussed in the Section 1.3.5,
when an embryo is released to the environment through vulva opening it is only 28-30
cells and at the end of embryonic development embryo is - 550 cells. Therefore, there is
substantial embryonic cell division outside the hermaphrodite. Interestingly, embryo starts
pharyngeal pumping at 760 min after the first cell cleavage and hatches at 800 min (80).
Therefore, embryo starts feeding (either through yolk vesicles or diet) before hatching and
the fact that postembryonic development is stimulated through feeding (80), indicates that
observed results are due to laid embryos not getting enough folates for embryonic
development to become a larva. Furthermore, as such observations were not present in
wild-type, gcp-2. I and gcp-2. 3 mutant worms suggest that gcp-2. 2 may play a role in folate
absorption within embryos. I suggest conducting an egg viability assay to strengthen these
finding in the future.
Folinic acid supplementation was effective in partly reversing the effect of SMX
induced folate synthesis inhibition on reproduction of wild-type worms but not in gcp-2
mutants. This indicates that Folinic acid is one of the forms of folate that contributes for C.
elegans ' progeny production and supplementation is only effective if all gcp-2 paralogs

remain intact in the animal. This observation further suggests that role of gcp-2 paralogs in
the metabolism of different folate derivatives may be complicated.
HPLC analysis showed that E. coli OP50 extract consists 5-formyl-THF, 5-methylTHF, DHF and THF (Table 6). In order to confirm which of these forms are required for
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C. elegans' reproduction and growth, I suggest conducting supplementation experiment
with each folate form on brood size and body length assay as demonstrated in this work.
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Figure 59. Comparative plot of the effect of SMX dependent folate inhibition on
body length of wild-type and gcp-2 C. elegans mutants.
Statistical significance was determined using two sample T-test (*p > 0.001 , **p < 0.001).
**p < 0.001 considered significant. The error bars represent± SEM.

144

Taken together, this chapter shows that restricting dietary folates reduces worm
progeny production and hinders development differently in cGCPII mutants in a
concentration dependent manner. Furthermore, cGCPII and gcp-2 paralogs, specifically
gcp-2.1 and gcp-2.2 paralogs, regulates folate dependent reproduction, embryonic and

post-embryonic development of C. elegans.

Chapter 4: Conclusions and Future Perspectives

In conclusion, the work presented established that cGCPII plays essential functions
in reproductive and developmental biology of C. elegans by mediating folate metabolism
as shown in Figure 60. Furthermore, the gcp-2.1 and gcp-2.2 paralogs play a significant
role in folate metabolism, reproduction, and post-embryonic development in C. elegans
where as gcp-2.3 may play a non-significant role. Furthermore, this work demonstrated,
for the first time, sheds light on the relationship between GCPII and folate metabolism in

C. elegans that has similar characteristics to the folate metabolism in humans. Thus, C.
elegans provides a genetically tractable model that can be used to study integrative aspects

of the GCPII dependent folate metabolism in the context of the whole animal level.
Further studies are needed to fully comprehend the hypothesis of the interaction
between GCPII , folate metabolism and embryonic/postembryonic developmental biology
of C. elegans at whole animal (in vivo) and molecular (in vitro) levels. Therefore,
suggestions for in vivo future studies is to generate a double mutant of lacking gcp-2.1 and
gcp-2.2 paralogs, generate a complete knockout lacking all three gcp-2 paralogs and

conduct drug assays using mammalian GCPII inhibitors as discussed in the Section 1.3.5.
Furthermore, suggestions for in vitro future studies is to clone cGCPII and gcp-2 paralogs
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to functionally characterise substrate level parameters such as pH dependence (indication
of tissue specific activity as different regions of the alimentary canal has specific pH
levels), saturability, substrate specificity, enzymatic activity (levels of folate-hydrolyzing
activity) and inhibition profile.
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Figure 60. Graphical representation of proposed GCPII function in folate mediated
reproductive and developmental biology of C. elegans.
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Appendix 1: Stock Solutions
1 M Potassium phosphate Buffer (pH 6.0): 108.3 g ofKH2P04, 35.6 g ofK2HP04

(Fisher Bio Reagents) was added to 1 L of sterilized Millipore water, stirred until dissolved.
Stored at 4 °C.
5 mg/mL Cholesterol stock: 0.5 g of cholesterol (95% Alfa Aesar) was added to

100 mL of absolute ethanol, stirred until dissolved. Stored at 4 °C.
10 mg/mL Nystatin stock: 0.5 g of nystatin was added to 50 mL of 70% ethanol,

stirred until dissolved. Stored at -20°C.
100 mg/mL Streptomycin stock: 1 g of streptomycin was added to 10 mL of

sterilized Millipore water, stirred until dissolved and filer-sterilized. Stored at -20°C.
1 M CaCh stock: 5.6 g of CaCh was added to 100 mL sterilized Millipore water

and stirred until dissolved. Stored at 4°C.
1 M MgS04 stock: 24.4 g ofMgS04 was added to sterilized Millipore water up to

100 mL and stirred until dissolved. Stored at 4°C.
150 mM FUdR stock: 0.37 g of FUdR (Acros Organics) was added to 10 mL

sterile Millipore water and stirred until dissolved. Stored at -20°C.
100 mg/mL Sulfamethoxazole Stock: 1 g of SMX (MP Biochemicals) was

dissolved in 9.5 mL of sterile Millipore water with 500 µL of 5N NaOH added to aid
dissolving of the compound. Filter sterilized using a 0.2 µm filter. Stored at -20°C.
SOX T AE Buffer Stock: 242 g of Tris base was dissolved in 700 mL of Millipore

water. Then 57 .1 mL of acetic acid and 100 mL of 0.5 M EDT A was added. Adjusted the
solution to a final volume of 1 L with Millipore water. Stored at room temperature. IX

working solution was prepared as needed by diluting stock solution with X50 Millipore
water.

Freezing Solution: 5.8g NaCl, 50mL IM KH2P04 (pH 6.0), 240mL glycerol was
added to 710 mL Millipore water. Sterilized by autoclaving at 121°C for 45 ruins. Then
added 300 µL 1M MgS04.

1 M Potassium Citrate pH 6.0: 20 g citric acid monohydrate, 293.5 g tripotassium citrate monohydrate was added to Millipore water to 1 L, stirred until dissolved
and sterilized by autoclaving. Stored at 4 °C.

Trace Metals Solution: Trace metals solution 1.86 g disodium EDTA, 0.69 g
FeS04 •7 HzO, 0.2 g MnCh•4 HzO, 0.29 g ZnS04 •7 HzO, 0.025 g CuS04 •5 HzO, HzO to
1 L Millipore water stirred until dissolved and sterilized by autoclaving. Stored at 4°C.

Appendix 2: Preparation of Liquid Growth Medium
S-Complete Solution: S-Complete solution was prepared by mixing sterilized 1 L
S-basal, 10 mL 1 M potassium citrate pH 6, 10 mL trace metals solution, 3 mL 1 M CaCh
and 3 mL 1 M MgS04. Stored at 4°C.

S-Basal Solution: 5.85 g NaCl, 1 g KzHP04, 6 g KH2P04 and 1 mL 5 mg/mL
cholesterol was added to Millipore water to 1 L, stirred until dissolved and sterilized by
autoclaving. Stored at 4 °C.

M-9 Buffer: M-9 Buffer was prepared by mixing 6 g Na2HP04, 3 g KH2P04, and
5 g NaCl in 1 L Millipore water, stirred until dissolved and autoclaved at 120°C for 45 min.
Then added 1 mL of 1 M MgS04. Stored at 4 °C.
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Appendix 3: RNAi Sequence Alignment Data

gcp-2.1

BLASTN 2 . 8 . 0+
Reference: Zheng Zhang, Scot t Schwartz, Lukas Wagner , and
Webb Miller (2000) , nA g r eedy algorithm for aligning DNA
sequences n , J Comput Bi o l 2 00 0 ; 7 (1- 2) :203-14 .

RID: 7GWRCGM0114
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Score
E
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>Quer y_203293
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Score = 1594 bits (863 ) ,
Expect= 0 . 0
Identities = 971/1027 (95%), Gaps = 27/1027 (3 %)
Strand=Plus/Mi nus
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AAAACCCATCAAATAACATCACGTAGAGTGTTTACAACGCAAATAACAGAGTACTGGACA
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I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111 11 111111111111111111111111

Sbjct

1630

AAAACCCATCAAATAACATCACGTAGAGTGTTTACAACGCAAATAACAGAGTACTGGACA
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ATGGAGATTTGGTTGATTATTTCCCTCAAGCCTTTTTTGGTTGGATTCAAGTCGTAACTG
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1111111111111111111111111 1 11111 1 11111111111111 I I I I I I I I I I I I I I

Sbjct

1570

ATGGAGATTTGGTTGATTATTTCCCTCAAGCCTTT TTTGG TT GGATTCAAGTCGTAACTG

1511
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211

TTGATCTGAATGAAGTTTTCTTTAGCATAAATTATATTATATCACTAACCGCATTCTGTA

270

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

1510

TTGATC TGAATGAAGTTTTCTTTAGCATAAATTATATTATATCACTAACCGCATTCTGTA

1451

Query
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CTCCTGCCATTAAAGAACTCGAGTATGAATCAGAATCGCTGACTGAAAACAGGACATGTC

330

I I I I I I I I I I I I I I 1111111111111111111111111111111111111111111111

Sbjct

1450

CTCCTGCCATTAAAGAACTCGAGTATGAATCAGAATCGCTGACTGAAAACAGGACATGTC
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TAGCTGAGGGATTGTGCATTGAAACGCCACGGGGGTTGATGAAGCATCTTTCCGTGCTGA
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I I I I I I I I I I I I I I I I I I I I I I I I I I 1111111111111111111111111111111111

Sbjct

1390

TAGCTGAGGGATTGTGCATTGAAACGCCACGGGGGTTGATGAAGCATCTTTCCGTGCTGA

1331
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AAACATAATGtttttttttAAATATGATAAAGTGGCAAACCTCTTTAATCTCTCATTGAC

450

I I I 111111111111111111111111111111111111111111111111111111111

Sbjct

1330

AAACATAATGTTTTTTTTTAAATATGATAAAGTGGCAAACCTCTTTAATCTCTCATTGAC
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1271

Query

451

CGCATTCACGTGTTTCGGGTCGTATGGATTCTGAGAGAAGCTGTGTTGTGTAAAATGGAT
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I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

1270

CGCATTCACGTGTTTCGGGTCGTATGGATTCTGAGAGAAGCTGTGTTGTGTAAAATGGAT

1211

Query

511

GGTTTCTTGGAAtttttttGACATTGTAAGTAAATCTTGAGCACTTTTTGAGAGAAGTGC
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I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct
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GGTTTCTTGGAATTTTTTTGACATTGTAAGTAAATCTTGAGCACTTTTTGAGAGAAGTGC
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Query

571

ATACTGTGTGCGTATATCTTCGAAATCGCTTCTCGAAACATTTATTCCGGAGATTGTTGT
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Sbjct
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ATACTGTGTGCGTATATCTTCGAAATCGCTTCTCGAAACATTTATTCCGGAGATTGTTGT
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TTTCAGTTGTGGGAGATAGGTTTTCAGCATGACTGACGCAAAATGTGTGGTATTCATTGG
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I I I I I I I I I I I I I I I I I I I I I I 11111111111111111111111111111111111111

Sbjct

1090

TTTCAGTTGTGGGAGATAGGTTTTCAGCATGACTGACGCAAAATGTGTGGTATTCATTGG
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GAGAATTACATCATCCGCAAACGTCCTGAAAAAAGTTCAGTTCTATTAAATCCTTAATTT
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I I I I I I I I I I I I I 1111111111111111111111111111111111111

111111 111
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GAGAATTACATCATCCGCAAACGTCCTGAAAAAAGTTCAGTTCTATTAAACCCTTAATTT
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TTATCAATATTCGGAAACTGAACATTTTGCATTGGAAATTATTTTTATATGCGGATTCAA

810
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Sbjct

970

TTATCAATATTCGGAAACTGAACATTTTGCATTGGAAATTATTTTTATATGCGGATTCAA
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811

GATATTaaaaaaaaaaa-CCTCCAGTTCCCCATGTTTTCCTTCAATTTATTATCAAAANC

869

11111111111111111

111111111111

1111111

1111111111111111111

I

Sbjct

910

GATATTAAAAAAAAAAAACCTCCAGTTCCC-ATGTTTT-CTTCAATTTATTATCAAAA-C
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TGATCNCGCNCAGTNNTAAATCTTAAAAGGTTGACCGCGTCCCNGGGGAAttttttaaaa

929

11111

111

1111

111111111111111111111111111

111

11111111111

Sbjct

853

TGATCACGCACAGTC-TAAATCTTAAAAGGTTGACCGCGTCCCTGGG--ATTTTTTAAAA
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ttttccnnagaaaannnncattttttgacttttttcaaaaaaaaaaCAAACCAAGNGACA

989

111111

111111

11111111111111111111111111111 I I I I

111

1111

Sbjct

796

TTTTCCT-AGAAAATCT-CATTTTTTGACTTTTTTCAAAAAAAAAACAAAC-AAGTGACA
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Query

990

TANAAANCCggggggggTANNAANCNCCAATTTTANCCCCGGGTTTTCCCAATTTTNAAN
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11

111

11111

11

11

I

I

I

1111111

I

I

11

111111

I

1111

11

Sbjct

739

TAGAAA-CCGGGTGGT-TATTAG-CTC-AATTTTATCTC - GG-TTTTCCTA-TTTT-AAT
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TAAAAANNCGNAAANCTTTTATTTTAACCAAATTTCCCCCNTTTTTAAAGGGCNTTAAAG
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11
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11
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11111111
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I

I
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I
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Sbjct
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TAGAAT--CG-AAATCTTT-ATTTTAACT - AATTTCTCACATTTT-AA-GG-CATTAAAG
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1110

NCTTAAC

1116
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Sbjct
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-CTTAAC

630
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BLASTN 2 . 8 . 0+
Reference : Zheng Zhang , Scott Schwartz , Lukas Wagner , and
Webb Miller (2000) , " A greedy algorithm for aligning DNA
sequences ", J Comput Biol 2000 ; 7(1 - 2) : 203 - 14 .

RID : 7GXOJZMP114
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Sequences producing significant alignments:
(Bits)
Value
Query_l5775
1561
0.0
ALIGNMENTS
>Query_15775
Length=ll 65
Score= 1561 bits (812),
Expect
Identities = 858/867 (99%) , Gaps
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Query
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0.0
6/867 (1%)

TTTGGATCAACAGCCCCATAAGCTCCAAGCATCATAATGATTGCTCACTAGAACAAACTT
1111111111111111111111

163

1111111111111111111111111111111111 I I I

Sbjct

1161

TTTGGATCAACAGCCCCATAAG-TCCAAGCATCATAATGATTGCTCACTAGAACAAACTT

1103

Query

164

GTCCGGTTCCTGACTTCCTTTGATATATCCCATTATATTTTGAATTTTTCTAAAATTCAA

223

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

1102

GTCCGGTTCCTGACTTCCTTTGATATATCCCATTATATTTTGAATTTTTCTAAAATTCAA

1043

Query

224

ACGCAATCTACTTATCAATTCTACAACTATAACTGACCGTTCTTCGTTTTCAGCATGAAC

283

1111111111111111111111111111111 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I

Sbjct

1042

ACGCAATCTACTTATCAATTCTACAACTATAACTGACCGTTCTTCGTTTTCAGCATGAAC

983

Query

284

GGTAACACGAAGTTTCTGATTGTTTATCAAGCCAGGTCCATAACGATATGTAACATTTAA

343

I I I I I I I I I I I I I I I I I I I 11111111111111111111111111111111111111111

Sbjct

982

GGTAACACGAAGTTTCTGATTGTTTATCAAGCCAGGTCCATAACGATATGTAACATTTAA

923

Query

344

CTTTCCTAAATGTAAACGCTGGTATTGTACAAATATACAGTTTCACTTTGAAACCTTGAA

403

I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111111111111

Sbjct

922

CTTTCCTAAATGTAAACGCTGGTATTGTACAAATATACAGTTTCACTTTGAAACCTTGAA

863

Query

404

AATCTGCATTCACTGCATCGCCTTTCATATTCTCAAATAATATTTGTGCTGTGGCATATG

4 63

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 11111111 1111111111111 111111111

Sbjct

862

AATCTGCATTCACTGCATCGCCTTTCATATTCTCAAATAATATTTGTGCTGTGGCATATG

803

Query

464

TAATTGGGAGCATGGGAATGGTAGGTATTTTCTTTTCATCTAACAACTGTAATTTTTATT

523

I I I I I I I I I I I I I I I I I I I I I I 11111111111111111111 1111 11111111111111

Sbjct

802

TAATTGGGAGCATGGGAATGGTAGGTATTTTCTTTTCATCTAACAACTGTAATTTTTATT

743

Query

524

TCAGTTTTTCCCAAGTGTTGAACAAATAAAACTACATCTTGTTCAGTTTTCTCTTTGAAA

583

I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111111

Sbjct

742

TCAGTTTTTCCCAAGTGTTGAACAAATAAAACTACATCTTGTTCAGTTTTCTCTTTGAAA

683

Query

584

AGATCTCCGATTGATGGGAACGCAGGTGTTCGTGGATCACCTAGGCCAATGTAGACTGAT

643

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

682

AGATCTCCGATTGATGGGAACGCAGGTGTTCGTGGATCACCTAGGCCAATGTAGACTGAT

623

Query

644

CCCATCTGGACTGTATTTGACGGCATTTTGTCTGTGTTTCCATAAGTTTCATCTAAAAAT

703

11111111111111111111111111111111111111111111111111111111 I I I I

Sbjct

622

CCCATCTGGACTGTATTTGACGGCATTTTGTCTGTGTTTCCATAAGTTTCATCTAAAAAT

563

Query

704

AAAAATAGGATAAATTTAAATAATATTTTTACAGCTCACTTGGCCCTGTTCCCAAACTGG

763

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

562

AAAAATAGGATAAATTTAAATAATATTTTTACAGCTCACTTGGCCCTGTTCCCAAACTGG

503

Query

764

CTACCTGTTTTGGATCCGAATAAACAAGACATGCTTTTGCACCTTTCTTTACAGCCATTT

823

1111111111111111111111111111111111111111 I I I I I I I I I I I I I I I I I I I I

Sbjct

502

CTACCTGTTTTGGATCCGAATAAACAAGACATGCTTTTGCACCTTTCTTTACAGCCATTT

443

Query

824

GGGCAATATTCCCTCGGTAATTAGAACTATACCTTGCCAGAAAATATTTTATCCTAAAAA

883

167

1111111111111111111111111111111111111111111

1111111111111111

Sbjct

442

GGGCAATATTCCCTCGGTAATTAGAACTATACCTTGCCAGAAA- TATTTTATCCTAAAAA

384

Query

884

CATAAACTTACCAATTTTCAAATTACATTTGGTANGTACCTTGGAGATCAATTNCCTAAC

943

1111 1 1111111111111111 1 1111111 I I

11

1111111 1

111111111

111111

Sbjct

383

CATAAACTTACCAATTTTCAAATTACATTTG- TATGTACCTTG- AGATCAATT - CCTAAC

Query

944

GACCCNAAAATATTCAATATCGCTTGG
111

Sbjct

326

I

111

327

970

11111111111111111

GACTCTAAA - TATTCAATATCGCTTGG

301

gcp-2.3
BLASTN 2 . 8 . 0+
Reference : Zheng Zhang , Sc ott Sc hwartz, Lukas Wagner , and
Webb Mill e r (2000 ) , "A greedy algorithm for aligning DNA
sequenc es " , J Comput Biol 2000 ; 7(1-2 ) : 203-14 .

RID : 7GX6B 6CK114

Query=
Length=l3 9 4

Score
E
Sequences producing significant alignments :
(Bits ) Value
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1450
0.0
ALIGNMENTS
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Length=lOOl
Score= 1 450 bits (754 ) ,
Expect
Identities= 824/837 ( 98 %) , Gaps
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Query

112
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9 / 837 ( 1 %)

TACCCTGATTGGACGACTCCCAACATTGTTGAAATACTCGAAGAAAATGGAGATGTATTT

171

111111111111111111111111111111111111111111111111111111111111

Sbjct

1

TACCCTGATTGGACGACTCCCAACATTGTTGAAATACTCGAAGAAAATGGAGATGTATTT

60

Query

172

TATAAAACTACGGGACGGAGCATATCTATTATTGAAGAAGAACAGAATGATTTGGTTTCT

231

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

61

TATAAAACTACGGGACGGAGCATATCTATTATTGAAGAAGAACAGAATGATTTGGTTTCT

120

Query

232

GAAATACAATGGCTTGCATATTCGGCTGATGGAACAGTTGAAGGAGATATTGTTTATGTC

291

111111111111111111111111111111111 1 1111 1 111111 1 1111111111111 1

Sbjct

121

GAAATACAATGGCTTGCATATTCGGCTGATGGAACAGTTGAAGGAGATATTGTTTATGTC

180

Query

292

AACAAAGGTACTCCAAAGGATATCGAGCATATAGAATCGTTGGGGATAGATCTGAAGGTT

351

111111111111111111111111111111111111111111111111111111111111

Sbjct

181

AACAAAGGTACTCCAAAGGATATCGAGCATATAGAATCGTTGGGGATAGATCTGAAGGTT

240

Query

352

TATTCCTAGTATAAAAAGTATTAATACAGCAGAAAACTTTTTAGGACAAAATTGTTCTCG

411

111111111111111111111111111111111111111111111111111111111111

168

Sbjct

241

TATTCCTAGTATAAAAAGTATTAATACAGCAGAAAACTTTTTAGGACAAAATTGTTCTCG

300

Query

412

CTAGATACAGTTCTAACTTCCGTGGTAACATAGCTCAAATGGCCGTCAAAAAAGGAGCAA

471

I I I I I I I I I 111111111111111111111111111111111111111111111111111

Sbjct

301

CTAGATACAGTTCTAACTTCCGTGGTAACATAGCTCAAATGGCCGTCAAAAAAGGAGCAA

360

Query

472

AAGCATGTCTTCTCTACTCAGACCCTATGCAAGTAGCAAGTCTTGGAACCGGACCAAGTG

531

11111111111111111111111111111111111111111111111 I I I I I I I I I I I I I

Sbjct

361

AAGCATGTCTTCTCTACTCAGACCCTATGCAAGTAGCAAGTCTTGGAACCGGACCAAGTG

420

Query

532

AGTTTTTCAAAATAATACAAGCAAACTTCAATCCGTTTTTTGTAATAGATAGTACATATG

591

11111111111111111111111111111111111111111 I I I I I I I I I I I I I I I I I I I

Sbjct

421

AGTTTTTCAAAATAATACAAGCAAACTTCAATCCGTTTTTTGTAATAGATAGTACATATG

480

Query

592

GAAGAACAGATAAGATGCCATCACATGCCGTTCAAAGAGGCACATGCTATGTTCAATCAG

651

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111111111111111111111111111111

Sbjct

481

GAAGAACAGATAAGATGCCATCACATGCCGTTCAAAGAGGCACATGCTATGTTCAATCAG

540

Query

652

GAGACCCCAGATTGCCGGCATTCCCTTCTATAAAAAATCTCTTCAAAGAAAAATCAGAGC

711

I I I I I I I I I I I I 111111111111111111111111111111111111111111111111

Sbjct

541

GAGACCCCAGATTGCCGGCATTCCCTTCTATAAAAAATCTCTTCAAAGAAAAATCAGAGC

600

Query

712

AAGAGGTTTTACAGATATTTAAAATTATAAAAACGTAGTATTTTTCCAGTTGTTGGATGG

771

11111111111111111111

I I I I I I I I I 111111111111 1 1111111111 1 111111

Sbjct

601

AAGAGGTTTTACAGATATTT - AAATTATAAAAACGTAGTATTTTTCCAGTTGTTGGATGG

659

Query

772

aaaaaaaGATCCCAACTATTCACTACTTCCCAATTCCATATAGCGCAGCGCAAANTTTTA

831

111111111111111111111111111

11111111111111111111 1 1111

11111

Sbjct

660

- AAAAAAGATCCCAACTATTCACTACTT - CCAATTCCATATAGCGCAGCGCAAA- TTTTA

716

Query

832

TTCGAAAAAATGAAAGGGAGACGCCGTCATTGCAGANTTTTCAAGGGTGGTTTGAAAATC

891

1111111111111 11

11111111 1 11111111111

1111111 1 1

11

1111

11111

Sbjct

717

TTCGAAAAAATGAAA - GGAGACGCCGTCATTGCAGA-TTTTCAAGGTTG- TTTG- AAATC

Query

892

TACATTTCCNCCGAAATTACAAGTTACtttttttAGGAAACCTTGACGTCCCATACC
111111111

Sbjct

773

11111111111 1 11111

592

GAAGAACAGA

1. 4
0/10 (0 %)

601

1111111111

Sbjct

97

GAAGAACAGA

106

Score = 19.9 bits ( 10) '
Expect
Identities = 10/10 ( 100 %) ' Gaps
Strand=Plus/Plus
Query

208

GAAGAACAGA

1. 4
0/10 (0 %)

217

1111111111

Sbjct

481

GAAGAACAGA

490

Score= 19.9 bits ( 10) '
Expect
Identities = 10/10 ( 100 %) ' Gaps
Strand=Plus/Minus
Query

169

TTTTATAAAA

1. 4
0/10 (0 %)

178

1111111111

Sbjct

67

TTTTATAAAA

58

Score= 19.9 bits ( 10) '
Expect
Identities = 10/10 (100 %) ' Gaps
Strand=Plus/Minus
Query

369

111111111

GTATTAATAC

1. 4
0/10 (0 %)

378

169

948

111111

TACATTTCCACCGAAATTACAAGTTAC - TTTTTTAGGAAAACTTGACGTCACATACC

Score = 19.9 bits ( 10) '
Expect
Identities = 10/10 (100 %) , Gaps
Strand=Plus/Plus
Query

1 1 1111111111

828

772

1111111111

Sbjct

267

GTATTAATAC

258

Score = 19 . 9 bits (10),
Expect
Identities= 10/10 (100 %), Gaps
Strand=Plus/Minus
Query

883

TTGAAAATCT

1. 4

0/10 (0 %)

892

1111111111

Sbjct

758

TTGAAAATCT

749

Score= 18 . 0 bits (9) , Expect= 5.2
Identities = 9/9 (100 %), Gaps = 0/9 (0 %)
Strand=Plus/Plus
Query

26

AGCGCAGCG

34

111111111

Sbjct

699

AGCGCAGCG

707

Score= 18 . 0 bits (9) , Expect= 5.2
Identities= 9/9 (100 %) , Gaps= 0/9 (0 %)
Strand=Plus/Plus
Query

1009

AAAAAATGA

1017

111111111

Sbjct

721

AAAAAATGA

729

Score= 18 . 0 bits (9) , Expect = 5 . 2
Identities= 9/9 (100 %) , Gaps= 0/9 (0 %)
Strand=Plus/Plus
Query

389

TTTTTAGGA

397

111111111

Sbjct

801

TTTTTAGGA

809

Score= 18 . 0 bits (9) , Expect= 5 . 2
Identities= 9/9 (100 %) , Gaps= 0/9 (0 %)
Strand=Plus/Minus
Query

574

TAATAGATA

582

111111111

Sbjct

91

TAATAGATA

83

Score= 18 . 0 bits (9) , Expect= 5 . 2
Identities= 9/9 (100 %) , Gaps= 0/9 (0 %)
Strand=Plus/Minus
Query

1133

AAAAGTTTT

1141

111111111

Sbjct

281

AAAAGTTTT

273

Score= 18 . 0 bits (9) , Expect= 5 . 2
Identities= 9/9 (100 %), Gaps= 0/9 (0 %)
Strand=Plus/Minus
Query

194

TATCTATTA

202

111111111

Sbjct

471

TATCTATTA

463
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3.15.4 Appendix 4: Extraction Buffer Components
Extraction Buffer contains 0.1 M phosphate buffer (pH 6.1), with 2% L-ascorbic
acid (w/v) (Fisher Chemicals) and 0.1 % 2-mercaptoethanol (v/v) (MP Biochemicals).
L-Ascorbic Acid: This is a water-soluble antioxidant that acts as a reducing agent
and thereby, helps to decrease oxidative stress (121).
2-Mercaptoethanol: This is a water-soluble thiol derived from hydrogen sulfide
and ethanol that acts as a reducing agent for disulfide bonds. Therefore, it protects
sulfhydryl groups from oxidation and thereby, helps to decrease oxidative stress (121).
Phosphate Buffer: This helps folate derivatives to dissolve as folates have low
solubility in water being more soluble in alkaline and saline media solutions (121).
Flushing with Nitrogen: This helps to reduce the levels of oxygen in folate extracts
and standards as dissolved oxygen levels have an inverse relationship with folate stability.
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Appendix 5: NMR Spectral Parameters, Conditions and Spectra
The spectral parameters and conditions are shown in each figure.

Folaic extract in DMSO d6
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lH-NMR Analysis of E.coli OPSO Folate Extracts.
1 mL of E. coli OPSO folate extract was dissolved in DMSO.
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lH-NMR Analysis of Folic Acid Standard.
100 mg of folic acid was dissolved in 1 mL DMSO (100 mg/mL concentration)
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lH-NMR Analysis of Bacterial Folate Extract and Folic Acid Standard Mixture.
1 mL of E. coli OP50 folate extract mixed with 1 mL of 100 mg/ml folic acid in DMSO.
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Appendix 6: E.coli OPSO Growth Curve

-o-Contro l (no SMX)
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Growth curve of E. coli OPSO treated with various concentrations of SMX.
50 µL from bacterial stock was inoculated into 100 mL Luria Bertani (LB) broth. Then the
culture was incubated at 35 °C and 250 rpm using an orbital shaker. Optical density was
recorded at 600 nm at regular intervals for 10 hours.
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